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Abstract
Extensive literature survey reveals that 8-Hydroxyquinoline (8-HQ), urea,
thiourea and piperazine exhibit wide biological activity profile such as anticancer,
anti-Alzheimer, anti-viral, antibacterial and antifungal activity. Novel urea and
thiourea-quinoline derivatives connected by piperazine moiety have been synthesized
and purified using appropriate techniques (extraction, crystallization and column
chromatography) followed by characterization using IR spectroscopy and NMR
spectroscopy (both 1H and 13C).
Biological activity, metal chelation properties and the photo-physical
properties were studied for these novel compounds. Anti-bacterial study shows
moderate activity for most of the compounds against P.aereginosa, S.aureus and
Enterococcus at concentration 250 µM. Antifungal study showed high potency
activity

for

only

compound,

N-(4-chlorophenyl)-4-((8-hydroxyquinolin-5-

yl)methyl)piperazine-1-carboxamide 62c against Botrytis cinerea which considered a
high-risk of development of fungicide resistance.
Metal chelation studies showed strong interaction between these
compounds and Cu2+ and Zn2+ metal ions. The trend of chelation strength for all
compounds follow the trend (Cu2+ > Zn2+ > Fe3+), where the Cu2+ forms the most
stable complex with all compounds. The stability of Fe3+complexes was the weakest
among all of them. In the photophysical study, the compounds showed a photo
induced electron transfer (PET) occurring from the 8-HQ ring (donor) to urea and
thiourea groups (acceptor) with the peprazine moiety serving as a spacer between
them. It was assumed that the efficiency varied according to the molecular stacking,
where the smaller size ring substituent resulted in higher PET efficiency. For the
same reason, the efficiency of urea compounds was higher than those of thiourea.
The metal chelation and photophysical studies of these compounds are
excellent indicators of the potential of these compounds in other biological activity
which are to be done in the near future including anticancer, anti-Alzheimer and antiParkinson diseases.
Keywords: 8-hydroxyquinoline, urea, thiourea, piperazine, anti-bacterial, antifungal,
metal chelation, photophysical and photo induced electron transfer.
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)Title and Abstract (in Arabic

تحضير مركباث جذيذة و ايجاد التطبيقاث البيولوجيت من مشتقاث اليوريا والثيويوريا
مع الكولونين
الملخص

أظهشث انعذَذ يٍ انذساعاث وعهً َطاق واعع أٌ يشخماث انهُذسوكغُكىَُىنٍُ و
انُىسَا و انزاَىسَا و انبُبشاصٍَ نذَها انعذَذ يٍ انخطبُماث انبُىنىجُت يزم يضاداث نهغشطاَاث
ونهضهاًَش ونهفُشوعاث ونهبكخُشَا و نهفطشَاث .حى حىنُف ويشخماث انُىسَا وانزُىسَا
وانكُُىنٍُ فٍ يشكباث جذَذة وحى سبطها بانبُبشاصٍَ ،رى حى حُمُخها باعخخذاو انخمُُاث انًُاعبت.
ونخأكذ يٍ بُُت انًشكباث او اعخخذاو جهاص انشٍَُ انًغُاطُغٍ انُىوٌ (كال انبشوحىٌ وانكاسبىٌ
) و جهاص انخحهُم انطُفٍ نألشعت ححج انحًشاء .حًج دساعت انخطبُماث انبُىنىجُت وخصائص
اسحباط انًعادٌ وانخصائص انفُضَائُت انضىئُت نهزِ انًشكباث انجذَذة.
و أظهشث انُخائج أٌ بعض يٍ انًشكباث انًصُعت نها فعانُت كًضاد نزالد أَىاع يٍ
انبكخ ُشَا عهً حشاكُض عانُت  ،ويشكب واحذ يٍ ضًٍ انًشكباث أظهش فعانُت عانُت عهً َىع
واحذ يٍ انفطشَاث عهً حشكُض يُخفض .و أظهشث َخائج اسحباط انًعادٌ وجىد اسحباط
لىٌ بٍُ هزِ انًشكباث وانًعادٌ انًخخاسة وأظهشث انذساعت أٌ انًشكباث حشحبظ اسحباط ورُك
يع انُحاط وانخاسصٍُ أيا اسحباطها بانحذَذ فهى اسحباط ضعُف جذا .وأضهشث َخائج انذساعت
انفُضَائُت انضىئُت أٌ انًشكباث حُمم اإلنكخشوٌ انًغخحذ يٍ انهُذسوكغُكىَُىنٍُ إنً
يجًىعخٍُ انُىسَا وانزُىسَا ،أيا انبُبشاصٍَ كاٌ بًزابت فاصم بُُهًا .واعخًذث كفاءة اَخمال
االنكخشوَاث عهً حكذَظ انًشكباث وحجًها ،حُذ أٌ انًشكب األصغش حجًا كاٌ األكزش
كفاءة .يشكباث انُىسَا بشكم عاو كاَج أكزش كفاءة فٍ َمم االنكخشوَاث يٍ
يشكباث انزاَىسَا .حعخبش َخائج اسحباط انًعادٌ وانخصائص انضىئُت يؤششا يًخاصا عهً
إيكاَاث هزِ انًشكباث فٍ حطبُماث بُىنىجٍ أخشي وانخٍ َجب انمُاو بها فٍ انًغخمبم انمشَب
بًا فٍ رنك يضاداث انغشطاٌ ويضاداث انضهاًَش ويضاداث انشهم انشعاػ.

مفاهيم البحث الرئيسية :الهيدروكسيكوينولين ،اليوريا ،الثايويوريا ،البيبرازين ،مضادات
للبكتيريا ،مضادات للفطريات ،ارتباط بالمعادن ،الخصائص الفيزيائية الضوئية.

ix

Acknowledgements
The past years were a great master journey full with achievements which I
am proud of, and experiences and knowledge I gained. I discovered through the
journey how every dream comes true once you really work hard and believe in it.
At the beginning, I am very grateful to ALLAH for making me strong enough to
overcome all challenges and obstacles that faced me through my master’s. Also, I
would like to express my appreciation to everyone who supported me throughout
my journey.
A special thank for his highness Mohammed Bin Zyied Al Nehian Crown
Prince of Abu Dhabi and Deputy Supreme Commander of the UAE's Armed
Forces, and Ministry of Presidential Affairs for the scholarship and for believing in
youths abilities and talents.
My sincere gratitude to my supervisor Dr.Mohammad Khasawneh and my
co-supervisor Dr. Haythem Saadeh for their endless support, motivation, patience
and sharing their pearls of wisdom with me during the journey. They provided me
with knowledge, help and all what I need to complete the research and the writing
of this thesis. I am thankful for their friendly advice, constructive criticism and
aspiring guidance during the master. It was a great privilege and honor to work
under their supervision.
I am extending my thanks to thank Dr. Abdelouahid Samadi for his
continuous support and encouragements. He taught me how to prioritize and
organize my work. He was very generous to share his knowledge and assign time to
follow up our work. Special thanks to Dr. Ahmed Alzamly for his endless support
and encourgment. Also, I would like to thanks Mr. Bassam Al-Hindawi for

x
introducing the instrumentation for me on my first year and for his endless support
and encouragements. In the metal chelation part, I would like to thank Ahmad
Alhalab for his valuable help and knowledge. Since part of this research project
was carried out in faculty of Medicine & Health Science, I am grateful to Dr.
Agness Sonnevend and her student Dania Darwich for their valuable guidance and
help in the Antibacterial part. Also, I would like to thanks Dr. Khaled El Tarabily
and Dr. Esam from Biology department for their endless help and support in the
biological activates parts.
I cannot express enough thanks to my friend Lamia who accompanied me
along the journey with generous support, endless encouragement and infinite
patience. She was always there when I need her and I am sure that this project will
need longer time to be finished without her valuable help. Also, I would like to
thanks My friend and labmate Ranem Kaddoura for her constant pursuit to provide
all required needs in a short time. I will not forget to thank my supportive master
friends: Manal, Reem Alzard, Noura Alshamsi, Khadeja, Salwa and Maram.
I am extremely grateful to my family, specially my parents, my father the
one who taught me that nothing is impossible in this life if you have the
determination and the faith to achieve it and my mother, the love of my life, l am
sure that all my difficulties facilitated because of her prayers. Special thanks from
my heart to my caring, loving, and supportive husband, Rashed Sultan, who
believes on my dreams and encourage me to follow and achieve them. My
husband’s family whom take care of Sultan in my absence starting with my
husband uncle, Mohammad Abdullah and his wife for hosting and overwhelmed
him by love. Also I want to express my thanks to my grandmother Moza, her son
Ali Abdullah, my father and mother in law, my brothers (Subaih, Ali, Salem, Saeed

xi
& Abdullah), sisters (Shikha, Moza, Fatima & Maryam), brother in laws ( Salem,
Ahmad & Abdullah) and sister in law (Moza, Fatema, Sendia & Maryam) for their
support and valuable prayers.
Finally, my thanks go to all the people who have supported me to complete
the research work directly or indirectly.

xii

Dedication

With all my love to
My husband, Rashed
My son, Sultan
Also, to my parents and family

xiii

Table of Contents
Title ............................................................................................................................... i
Declaration of Original Work ...................................................................................... ii
Copyright .................................................................................................................... iii
Advisory Committee ................................................................................................... iv
Approval of the Master Thesis ..................................................................................... v
Abstract ...................................................................................................................... vii
Title and Abstract (in Arabic) ................................................................................... viii
Acknowledgements ..................................................................................................... ix
Dedication .................................................................................................................. xii
Table of Contents ...................................................................................................... xiii
List of Tables.............................................................................................................. xv
List of Figures ........................................................................................................... xvi
List of Abbreviations.................................................................................................. xx
Chapter 1: Introduction ................................................................................................ 1
1.1 Overview……………. ............................................................................... 1
1.2 8-Hydroxyquinoline derivatives ............................................................... 2
1.2.1 Biological of 8-HQ derivatives ........................................................ 2
1.2.1.1 Anticancer of 8-HQ derivatives................................................ 3
1.2.1.2 Activity against Alzheimer's and Parkinson's diseases ............ 4
1.2.1.3 8-HQ derivatives as antibiotic .................................................. 8
1.2.1.4 Anti-HIV of 8-HQ derivatives.................................................. 9
1.2.1.5 Other activetes of 8-HQ derivatives ....................................... 10
1.2.1.6 Photophysical properites of 8-HQ derivatives ....................... 11
1.3 Urea and thiourea derivatives................................................................... 13
1.3.1 Biological activity of urea and thiourea derivatives .................... 15
1.3.1.1 Anticancer of urea and thiourea derivatives ........................... 15
1.3.1.2 Anti-AD of urea and thiourea derivatives .............................. 17
1.3.1.3 Urea and thiourea derivatives as antibiotic ............................ 17
1.3.1.4 Other activity for urea and thiourea derivatives ..................... 19
1.4 Piperazine derivative ................................................................................ 20
1.4.1 Biological activities of piperazine derivatives ............................. 21
1.4.1.1 Anticancer activities of piperazine derivatives....................... 22
1.4.1.2 Anti-AD activities of piperazine derivatives .......................... 22
1.4.1.3 Antiviral activities of piperazine derivatives .......................... 23
1.5 Research plan ........................................................................................... 24

xiv
Chapter 2: Material and Methods............................................................................... 25
2.1 Chemistry experimental ........................................................................... 25
2.2 Biological activities experimental ............................................................ 34
2.2.1 Antibacterial activity ...................................................................... 34
2.2.2 Antifungal activity.......................................................................... 35
2.3 Metal chelation experimental ................................................................... 36
2.4 Photophysical experimental ..................................................................... 36
Chapter 3: Results and Discussion ............................................................................. 38
3.1 Overview of synthesis .............................................................................. 38
3.2 Biological activities.................................................................................. 44
3.2.1 Antibacterial activity ...................................................................... 44
3.2.2 Antifungal activity.......................................................................... 46
3.3 Metal chelation results and discussion ..................................................... 47
3.3.1 Calibration curve of compound 62b.HCl ....................................... 48
3.4 Photophysical results and discussion ....................................................... 52
Chapter 4: Conclusion ................................................................................................ 55
References .................................................................................................................. 57
Appendix .................................................................................................................... 66

xv

List of Tables
Table 1: Compounds (61a-i) and (62a-d) substitution ............................................... 24
Table 2: The concentration of the compounds (61a-i) and (62a-d)
at which the 6 type of chosen pathogenic bacteria grow in ......................... 45
Table 3: The concentration of the compounds (61a-i) and (62a-d)
at which the mycelial growth of some selected plant
diseases causal fungi grow in ....................................................................... 46
Table 4: The fluorescence peak positions (nm) and excited-state
lifetimes (ns) for thiourea 8-HQ derivatives in solid state
at room temperature ..................................................................................... 53
Table 5: The fluorescence peak positions (nm) and excited-state
lifetimes (ns) for urea 8-HQ derivatives in solid state
at room temperature ..................................................................................... 54

xvi

List of Figures
Figure 1: Structure of quinoline ................................................................................... 1
Figure 2: Structure of 8-HQ ......................................................................................... 2
Figure 3: Structures for compounds 3-7 containing the 8-HQ moiety
that shows anticancer activity ...................................................................... 4
Figure 4: Structure of: (8) clioquinol (9) donepezil (10) hybrid-type
drug of clioquinol and donepezil. ................................................................ 6
Figure 5: Chemichal structures of compounds 11-14 containing the
8-HQ moiety and having metal chelation properties. .................................. 7
Figure 6: Chemichal structures of compounds 15-17 containing the
8-HQ moiety and work as metalloenzymes inhibitors ................................ 8
Figure 7: Chemichal structures of compounds 18-20 containing the
8-HQ moiety that have antibiotic activity ................................................... 9
Figure 8: Chemichal structures of compounds 21-23 containing the
8-HQ moiety and work as HIV integrase inhibitors. ................................ 10
Figure 9: Chemichal structures of compounds 24-25 containing the
8-HQ moiety .............................................................................................. 11
Figure 10: The PET process involves an electron transfer from an
excited donor (D*) to an acceptor molecule, forming
a radical ion species (D+/A-)* ................................................................ 12
Figure 11: 8-HQ derivative with electro-optical property ......................................... 13
Figure 12: The Wöhler synthesis of urea ................................................................... 13
Figure 13: Two methods (A) and (B) for synthesizing urea ..................................... 14
Figure 14: Two methods (A) and (B) for synthesizing thiourea………………...…..14
Figure 15: Chemichal structure of diethylbarbituric acid ......................................... 15
Figure 16: Structures for compounds 31-33 containing urea and
thiourea as anticancer drugs. ................................................................... 16
Figure 17: Structures for compounds 34-35 containing urea and
thiourea that have anticancer activity ...................................................... 16
Figure 18: Structures for compounds 36-37containing urea and
thiourea that have anti-AD activity ......................................................... 17
Figure 19: Structures for compounds 38-41 containing urea and
thiourea that have antibacterial and antifungal activity. ......................... 18
Figure 20: Structures for compounds 42-43 containing urea that have
anti-viral activity .................................................................................... 19
Figure 21: Structure of 1-benzyl-3-(p-tolyl)urea ....................................................... 19
Figure 22: Structure for thiourea containing compound with sugar
lowering activity. ..................................................................................... 20
Figure 23: Synthesis of piperazine ........................................................................... 20
Figure 24: Structure of urapidil and nefazodone........................................................ 21

xvii
Figure 25: Structures for compounds 49-50 containing piperazine
that have anticancer activity .................................................................... 22
Figure 26: Structures for compounds 51-52 containing piperazine
that have anti-AD activity ...................................................................... 23
Figure 27: Structures for compounds 53-54 containing piperazine
that have anti-viral activity...................................................................... 23
Figure 28: General synthesis of hydroxyquinoline-carbothioamide
(thiourea) (61a-i) and hydroxyquinoline –carboxamide
(urea) derivatives (62a-d) ........................................................................ 24
Figure 29: T Synthesis scheme of key intermediate 58 ............................................ 25
Figure 30: The metal chelation study was done for these 10 salt
compounds ............................................................................................. 39
Figure 31: The reaction of compound 55 with piperazine 63 .................................... 40
Figure 32: The reaction of compound 55 with Boc-piperazine 56 ............................ 40
Figure 33: Suggested mechanism for synthesis compounds 57 & 58 ........................ 41
Figure 34: The reaction of compound 55 with Boc-piperazine 56 ............................ 41
Figure 35: Suggested mechanism for Compounds (61a-i) and (62a-d) ................... 42
Figure 36: The metal chelation study was done for these 10 salt
compounds .............................................................................................. 47
Figure 37: Calibration curve for compound 62b.HCl ................................................ 48
Figure 38: UV titration of 62b.HCl with Cu2+ ........................................................... 49
Figure 39: UV titration of 62b.HCl with Zn2+ ........................................................... 50
Figure 40: UV titration of 62b.HCl with Fe3+ ............................................................ 51
Figure 41: The 8 compounds that their photophysical properties
were studied............................................................................................. 52
Figure 42: The fluorescence peak for compounds 62b, 61c and
control...................................................................................................... 53
1
Figure 43: H-NMR (400 MHz, D2O) spectra of compound 55 ................................ 66
Figure 44: 13C-NMR (100 MHz, CDCl3) spectra of compound 55 ........................... 66
Figure 45: 1H-NMR (400 MHz, D2O) spectra of compound 57 ................................ 67
Figure 46: 13C-NMR (100 MHz, CDCl3) spectra of compound 57 ........................... 67
Figure 47: 1H-NMR (400 MHz, D2O) spectra of compound 58 ................................ 68
Figure 48: 13C-NMR (100 MHz, CDCl3) spectra of compound 58 ........................... 68
Figure 49: 1H-NMR (400 MHz, DMSO) spectra of compound 61a .......................... 69
Figure 50: 13C-NMR (100 MHz, DMSO) spectra of compound 61a......................... 69
Figure 51: 1H-NMR (400 MHz, DMSO) spectra of compound 61b.......................... 70
Figure 52: 13C-NMR (100 MHz, DMSO) spectra of compound 61b ........................ 70
Figure 53: 1H-NMR (400 MHz, DMSO) spectra of compound 61c .......................... 71
Figure 54: 13C-NMR (100 MHz, DMSO) spectra of compound 61c......................... 71
Figure 55: 1H-NMR (400 MHz, DMSO) spectra of compound 61d.......................... 72
Figure 56: 13C-NMR (100 MHz, DMSO) spectra of compound 61d ........................ 72
Figure 57: 1H-NMR (400 MHz, DMSO) spectra of compound 61e .......................... 73
Figure 58: 13C-NMR (100 MHz, DMSO) spectra of compound 61e......................... 73

xviii
Figure 59: 1H-NMR (400 MHz, DMSO) spectra of compound 61f .......................... 74
Figure 60: 13C-NMR (100 MHz, DMSO) spectra of compound 61f ......................... 74
Figure 61: 1H-NMR (400 MHz, DMSO) spectra of compound 61g.......................... 75
Figure 62: 13C-NMR (100 MHz, DMSO) spectra of compound 61g ........................ 75
Figure 63: 1H-NMR (400 MHz, DMSO) spectra of compound 61h.......................... 76
Figure 64: 13C-NMR (100 MHz, DMSO) spectra of compound 61h ........................ 76
Figure 65: 1H-NMR (400 MHz, DMSO) spectra of compound 61i .......................... 77
Figure 66: 13C-NMR (100 MHz, DMSO) spectra of compound 61i ......................... 77
Figure 67: 1H-NMR (400 MHz, DMSO) spectra of compound 62a .......................... 78
Figure 68: 13C-NMR (100 MHz, DMSO) spectra of compound 62a......................... 78
Figure 69: 1H-NMR (400 MHz, DMSO) spectra of compound 62b.......................... 79
Figure 70: 13C-NMR (100 MHz, DMSO) spectra of compound 62b ........................ 79
Figure 71: 1H-NMR (400 MHz, DMSO) spectra of compound 62c .......................... 80
Figure 72: 13C-NMR (100 MHz, DMSO) spectra of compound 62c......................... 80
Figure 73: 1H-NMR (400 MHz, DMSO) spectra of compound 62d.......................... 81
Figure 74: 13C-NMR (100 MHz, DMSO) spectra of compound 62d ........................ 81
Figure 75: Infrared spectra for (61a), (61b) and (61c) ............................................... 82
Figure 76: Infrared spectra for (61d), (61e) and (61f) ............................................... 83
Figure 77: Infrared spectra for (61g), (61h) and (61i) ............................................... 84
Figure 78: Infrared spectra for (62a), (62b) and (62c) ............................................... 85
Figure 79: Infrared spectra for (62d) .......................................................................... 86
Figure 80: 61a.HCl Calibration table and curve ........................................................ 87
Figure 81: UV titration of 61a.HCl with Cu2+ ........................................................... 87
Figure 82: UV titration of 61a.HCl with Zn2+............................................................ 88
Figure 83: 61b.HCl Calibration table and curve ........................................................ 88
Figure 84: UV titration of 61b.HCl with Cu2+ ........................................................... 89
Figure 85: UV titration of 61b.HCl with Zn2+ ........................................................... 89
Figure 86: 61c.HCl Calibration table and curve ........................................................ 90
Figure 87: UV titration of 61c.HCl with Cu2+ ........................................................... 90
Figure 88: UV titration of 61c.HCl with Zn2+............................................................ 91
Figure 89: UV titration of 61c.HCl with Fe3+ ............................................................ 91
Figure 90: 61d.HCl Calibration table and curve ........................................................ 92
Figure 91: UV titration of 61d.HCl with Cu2+ ........................................................... 92
Figure 92: UV titration of 61d.HCl with Zn2+ ........................................................... 93
Figure 93: 61h.HCl Calibration table and curve ........................................................ 93
Figure 94: UV titration of 61h.HCl with Cu2+ ........................................................... 94
Figure 95: UV titration of 61h.HCl with Zn2+ ........................................................... 94
Figure 96: 61i.HCl Calibration table and curve ......................................................... 95
Figure 97: UV titration of 61i.HCl with Cu2+ ............................................................ 95
Figure 98: UV titration of 61i.HCl with Zn2+ ............................................................ 96
Figure 99: 62a.HCl Calibration table and curve ........................................................ 96
Figure 100: UV titration of 62a.HCl with Cu2+ ......................................................... 97
Figure 101: UV titration of 62a.HCl with Zn2+.......................................................... 97

xix
Figure 102: 62b.HCl Calibration table and curve ...................................................... 98
Figure 103: UV titration of 62b.HCl with Cu2+ ......................................................... 98
Figure 104: UV titration of 62b.HCl with Zn2+ ......................................................... 99
Figure 105: UV titration of 62b.HCl with Fe3+ .......................................................... 99
Figure 106: 62c.HCl Calibration table and curve .................................................... 100
Figure 107: UV titration of 62c.HCl with Cu2+ ....................................................... 100
Figure 108: UV titration of 62c.HCl with Zn2+........................................................ 101
Figure 109: UV titration of 62c.HCl with Fe3+ ........................................................ 101
Figure 110: 62d.HCl Calibration table and curve .................................................... 102
Figure 111: UV titration of 62d.HCl with Cu2+ ....................................................... 102
Figure 112: UV titration of 62d.HCl with Zn2+ ....................................................... 103
Figure 113: Steady-state emission spectra for control, compounds
(61a-b) and (62a-b) in solid state at room temperature
(
) ..................................................................................... 104
Figure 114: Steady-state emission spectra for compounds
(61c-d) and (61h-i)in solid state at room temperature
(
) ..................................................................................... 105

xx

List of Abbreviations
Excited-State Lifetime
3-DG

3-deoxyglucosone

6- OHDA

6-hydroxydopamine

8-HQ

8-Hydroxyquinolines

A*

Anionic Species Intermediate

ABAD

Amyloid-β Binding Alcohol Dehydrogenase

AChE

Acetylcholinesterase

AD

Alzheimer's Disease

AGE

Advanced Glycation End Product

Ap

PET Acceptor Molecule

ATP

Adenosine Tri-Phosphate

Aβ

Amyloid-β

B4 virus

Coxsackie Virus

BODIPY

Boron-dipyrromethane

BuChE/ BChE

Butyrylcholinesterase

cat

Cathepsin

CDCL3

Deuterated Chloroform

DAS

Decay-associated Spectra

DIPMA

Diisopropyl Methyl Amine

DMDTC

S, S-dimethyl Dithiocarbonate

DMSOD

Dimethyl Sulfoxide

DNA

Deoxyribonucleic Acid

xxi
Dp

PET Donor Molecule

E

PET Efficiency

EC50

The Drug Concentration That Gives Half-maximal Response

FDA

Food and Drug Administration

FT-IR

Fourier Transform Infrared Radiometer

GO

Glyoxal

H1-H16

Haemagglutinin (1-16)

HCl

Hydrochloric Acid

HIV

Human Immunodeficiency Virus

HMBC

Heteronuclear Multiple-Bond Correlation

HSQC

Heteronuclear Single Quantum Coherence

HUMO

Highest Occupied Molecular Orbital

IC50

The Half Maximal inhibitory Concentration

IRF

Instrument Response Function

knr

Non-raditively Emission

kr

Radiatively Emission

LUMO

Lowest Unoccupied Molecular Orbital

MAO

Monoamine Oxidase

MGO

Methylglyoxal

MHA

Molten Mueller Hinton Agar

MMP

Matrix Metalloproteinase

MP

Melting Point

MT-4

Human Leukemia T-cell

MTDLs

Multi-targeting Directing Ligand Strategy

N*

Neutral Excited State

xxii
N1-N9

Neuraminidase (1-9)

NMR

Nuclear Magnetic Resonance

o

Ortho Positions

p

Para Positions

PD

Parkinson's Disease

PDA

Potato Dextrose Agar Medium

PET

Photo Induced Electron Transfer

PL

Photoluminescence

S0

Ground State

S1

Eexcited State

T*

Tetautomer Form

TCSPC

Time-correlated Single-photon Counting

TEA

Triethylamine

TFA

Trifluoroacetic Acid

THF

Tetrahydrofolate

TIPEA

Triisoproplyl Ethyl amine

TLC

Thin Layer Chromatography

UV

Ultra Violet

WHO

World Health Organization

1

Chapter 1: Introduction
1.1 Overview
The synthesis of novel bioactive compounds is the target of many research
groups and pharmaceutical companies these days. Heterocyclic compounds are
among the most common bioactive compounds, which makes them very well-known
in many pharmaceutical drugs that exhibit a large variety of interesting biological
activities. According to the US FDA, the most common heterocyclic compounds that
are present in drugs are those that are containing nitrogen (Edon & David, 2014). Of
special interest, the quinoline derivatives which are one of the famous nitrogen
containing heterocyclic aromatic compound. They are also known as 1-azanapthalene or benzo[b]pyridine. Quinoline 1 (Figure 1) has a wide range of
biological and pharmacological activities due to its non-toxicity to humans. It was
reported that quinoline ring possesses anti-cancer (Jain et al., 2016), anti-tubercular
(Keri & Patil, 2014), antimalarial (Kaur et al., 2010) and anti-microbial activity (ElGamal et al., 2016).

Figure 1: Structure of quinoline

The focus of this thesis is to design and synthesize a group of novel
derivatives of 8-hydroxyquinoline containing urea and thiourea moieties and study
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their biological activity including the metal chelation properties. In the following
sections, a detailed review of the recent literature describing novel derivatives of 8HQ is given. This review includes recent developments of the bioactivities of 8-HQ
derivatives and their use as promising bioactive compounds.
1.2 8-Hydroxyquinoline derivatives
8-Hydroxyquinoline 2 ( 8-HQ ) derivatives are very wide-spread derivatives
of quinoline. They are also known as 8-quinolinols, hydroxybenzopyridine,
phenopyridine or oxines. These derivatives vary in activity according to the position
and the nature of the substituents on the phenyl ring. 8-HQ contains OH group,
which is a strongly activating group toward electrophilic aromatic substitution
reaction directing substituent to the ortho (position 7 (C-7)) and para (position 5 (C5)) positions as shown in (Figure 2) (Valentina & Graziella, 2016).

Figure 2: Structure of 8-HQ

1.2.1 Biological activity of 8-HQ derivatives
8-HQ and its derivatives have excellent bioactivity profile including
anticancer, metal-chelation, HIV integrase inhibition, metalloenzymes inhibition,
antibacterial, antimalarial, antifungal and anti-schistosomal activity.
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1.2.1.1 Anticancer activity of 8-HQ derivatives
World Health Organization (WHO) reported that cancer is the second most
frequent cause of death in the world (Moret et al., 2009). Figure 3 illustrates five
examples of 8-HQ derivatives that have substitutions on the para and /or ortho
position of the phenyl group and work as anticancer agents. For example, 5nitrosoquinolin-8-ol (compound 3) was tested on breast cancer cell lines and animal
models with leukemic cells and was found as anticancer agent that target the
proliferative properties in the cancer cells by inhibiting the activity of histone
deacetylase (Martirosyan, 2006). Additionally, Compound 5 was found to inhibit
cathepsin B (catB), which is a lysosomal cysteine protease enzyme. The abnormality
of this enzyme is associated with many diseases including cancer. Overexpression of
catB in tumor cells leads to an increase in the rate of extracellular matrix degradation
which give the tumor cells space to amplify and immigrate. CatB have dual activity
as endopeptidase and carboxyopeptidase unlike most of cathepsins which are
endopeptidases only (Ruan et al., 2015). Compound 5 also showed selectivity toward
catB over catH and catL, in comparison with the commercial nitroxoline drug
(compound 4) (Sosič et al., 2013). Compounds 6 and 7 contain two moieties of 8HQ versus one moiety in compound 3 and 5. Both of compounds 6 and 7 show high
potency against various cancer cell lines (Moret et al., 2009).
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Figure 3: Structures for compounds 3-7 containing the 8-HQ moiety that
shows anticancer activity

1.2.1.2 Activity against Alzheimer's disease (AD) and Parkinson's disease (PD)
Alzheimer's disease (AD) and Parkinson's disease (PD) are neurodegenerative
diseases that are considered to be among the top word leading causes of death along
with cancer and heart disease (Anand et al., 2014). Several factors are involved in
AD including amyloid-β (Aβ) accumulation and aggregation in the form of
extracellular brain plaques (Budimir, 2011), tau protein hyperphosphorylation,
oxidative stress, imbalance in the calcium level, abnormality in mitochondrial
function and collapsing of synaptic transmission. Also, the decrease in the
acetylcholinesterase (AChE)

levels

and

the

increase

or

unchanged

butyrylcholinesterase (BuChE) levels play a role in AD (Nordberg et al., 2013). All
these factors are leading to diminished learning, memory loss and emotional
behavior (Dias & Viegas, 2014). Parkinson's disease is a dopamine production
disorder in the substantia nigra nerve cells in the brain. Dopamine is an important
neurotransmitter that sends messages to control body movement including walking,
talking and writing. Rigid muscles are commonly associated with PD, which can
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occur in any part of the body with pain and limited the motion range. Tremors is
another symptom, where the hands shake even at rest (Mantri et al., 2018). Many PD
therapies depend on inhibiting monoamine oxidase-B (MAO-B), an enzyme found in
the outer membrane of the mitochondria, the function of which is to break down
dopamine (Song et al., 2012).
Metal-chelation was reported as one of the properties required for the control
of AD and PD (Shamloo et al., 2018). 8-HQ was shown to exhibit this property due
to the position of OH group which is close to the nitrogen and therefore it can chelate
with certain metals such as copper, zinc and iron. Many studies show that these three
bio-metals are involved in AD by causing Aβ peptide aggregation and enhancing the
Aβ induced reactive oxygen species production (Budimir, 2011). In PD, the excess of
iron ion in the brain affect the neurotransmitter function. AD and PD therapies aim to
remove the excess of these metal ions to maintain homeostasis (Ward & Crichton,
2012). For example, compound 10 (Figure 4) a hybrid-type multi-target that target
several AD factors drug of two anti-AD drugs, clioquinol (compound 8) and
donepezil (compound 9) has good antioxidant properties and chelation properties
with zinc (II) and copper (II). In addition, it has in vitro anti-BuChE and anti-Aβ
aggregating activity (Prati et al., 2016).
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Figure 4: Structure of: (8) clioquinol (9) donepezil (10) hybrid-type drug of
clioquinol and donepezil

Several 8-HQ derivatives with anti-AD and PD are in the research and
development stage (Figure 5). Compound 11 chelates strongly with iron (III), have
antioxidant characteristic and have selectivity for MAO-B inhibition (Zheng et al.,
2005). Both 12 and 13 are novel neuroprotective agents with strong iron chelation
and good brain permeability and

have anti-PD activity (Shachar et al., 2004).

Compound 12 has the ability to prevent 6-hydroxydopamine (6-OHDA) from
attacking dopamine in PD mouse model (Zheng et al., 2005). 6-OHDA is dopamine
with extra OH attached to it that used as a model of PD because it is able to damage
the nigrostriatal dopaminergic (Tieu, 2011). Compound 13 has Inhibition selectivity
toward brain MAO. Compound 14 works with multi-targeting directing ligand
strategy (MTDLs) as MAO inhibitor, acetylcholine inhibitor and it has a metal
chelating feature (Wang et al., 2014).
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Figure 5: Chemichal structures of compounds 11-14 containing the 8-HQ
moiety and having metal chelation properties

Metalloproteins is a group of proteins that contain metal ions as cofactors
such as Mn, Fe, Co, Ni, Cu and Zn in their structure. The presence of the cofactors
facilitates bio-targeting these proteins to inhibit them. Inhibiting metalloprotein is
desirable for different applications and therapeutic purposes. It was reported that
metalloproteins are associated with several diseases including cancer, inflammatory,
cardiovascular

and

neurodegenerative

diseases.

For

example,

matrix

metalloproteinase-2 and 8 (MMP-2) and (MMP-8) are metalloenzymes that target
cancer (Wang et al., 2018). It was reported that 8-HQ derivatives with substituents
on 5 and 7 positions such as compounds 15, 16, and 17 (Figure 6) work as
metalloenzymes inhibitors. These compounds activate MMP-2 inhibition by binding
to zinc(II) through quinolone nitrogen and the hydroxyl oxygen atoms with IC 50 in
the micromolar range (Jacobsen et al., 2011).
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Figure 6: Structures of compounds 15-17 containing the 8-HQ moiety and
work as metalloenzymes inhibitors

1.2.1.3 8-HQ derivatives as antibiotics
Antibiotics are medicines that fight certain infections either by blocking the
microorganisms reproducing process or killing the microorganisms. Over decade,
antibiotics have saved patients’ lives and played an important role in medicine and
the progress of surgery such as cardiac surgery or organ transplants. However the
long-term misuse/overuse of these antibiotics made them less effective to treat
infection as they were because the microorganisms develop resistance against the
antibiotics (Ventola, 2015). Drug resistance is one of the biggest challenges that face
pharmaceutical companies in the current days. Drug resistance is the ability of
microorganisms such as bacteria, fungi , and parasites to grow in the presence of the
drug that kills them normally (Revie et al., 2018). Therefore, the development of new
drugs should be continuous to overcome the development of the drug resistance in
these microorganisms (Mekouar et al., 1998). 8-HQ (2) itself exhibits antimicrobial
activity with high potency against gram-positive bacteria including diploid fungi and
yeast. The halogenated derivatives 8-HQ such as 7-bromo-8HQ 18 (Figure 7) and
clioquinol 8 (Figure 4) show potent growth inhibition activity against gram-negative
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bacteria. Nitroxoline 4 (Figure 3) exhibits antibacterial activity with high potency
against Aeromonas hydrophila and growth inhibition activity against P. aeruginosa
(Cherdtrakulkiat et al., 2016). In addition, 8-HQ derivatives such as compounds 19
and 20 show in vitro antifungal activity against several strains of human pathogenic
fungi with higher potency than the commercial fluconazole drug (Musiol et al.,
2006).

Figure 7: Structures of compounds 18-20 containing the 8-HQ moiety that
have antibiotic activity

1.2.1.4 Anti-HIV activity of 8-HQ derivatives
HIV integrase inhibitors are drugs used to prevent the HIV genome
transformation to the host cell DNA. Because of the excellent antiviral activity of 8HQ derivatives, they are used to target HIV-1 integrase (IN). For example,
compound 20 (Figure 8) is one of the styrylquinoline derivatives that shows potent
HIV integrase inhibition activity and potent effect against HIV replication with low
cytotoxicity (Mekouar et al., 1998). Compounds 21 and 22 show viral replication
inhibition for MT-4 cells, human leukemia T-cell which is highly sensitive to HIV1,
with low micromolar EC50 and low toxicity (Serrao et al., 2013).
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Figure 8: Structures of compounds 21-23 containing the 8-HQ moiety and
work as HIV integrase inhibitors

1.2.1.5 Other biological activities of 8-HQ derivatives
It was reported that 8-HQ derivatives have anti-schistosomal activity (Eweas
et al., 2013). Schistosomiasis is a parasitic disease caused by worm infection of the
intestines and/or the urinary tract.

Compound 23 in (Figure 8) is an anti-

schistosomal agent with high potency. In vitro study shows that this compound can
decrease eggs laying in adult worms and minimize egg deposition by binding with
thioredoxin glutathione reductase which is a necessary protein for schistosome
survival (Eweas et al., 2013).
Other 8-HQ derivatives (e.g. compound 24 Figure 9) showed good activity as
glyoxal (GO), methylglyoxal (MGO) scavenger and as Advanced glycation
end product (AGE) inhibitor. AGE is a protein modification caused by reactive αdicarbonyl species, such as GO, MGO and 3-deoxyglucosone (3-DG). It was
reported that reactive α-dicarbonyl species is responsible for developing diabetic
complications (Audic et al., 2013).
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Figure 9: Structures of compounds 24-25 containing the 8-HQ moiety

1.2.1.6 Photophysical properties of 8-HQ derivatives
Fluorescence is the emission of light (photon) that occurs when electron
relaxes from the singlet excited state to the ground state. Photon-induced electron
transfer (PET) is an electron transfer in the excited state from a donor molecule (D)
to an acceptor (A) molecule forming a radical ion. Either the electron donor or
acceptor can be the excited fluorophore depending on the oxidation and reduction
potential of the ground and excited states. Fluorophores are compounds that can reemit light upon excitation, see Figure 10. There are many applications for PET such
as sensing for chemical and biological analyte (Yang et al., 2018), imaging tissues
and drug delivery (Ayoob et al., 2018), molecular logic gates (Silva and Uchiyama,
2011) and color tuning (Gui et al., 2018).
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Figure 10: The PET process involves an electron transfer from an excited donor (D*)
to an acceptor molecule, forming a radical ion species (D+/A-)*

8HQ 2 itself is a weak fluorophore in most media and has a short lifetime in
the existed state. This was explained through the occurrence of proton transfer in the
initial neutral excited state (N*) forming an anionic species intermediate (A*) and
eventually a tautomer form (T*) (Park et al., 2016). However, when 8-HQ binds
metal ions, the resulted meal complexes show high emission yield. Such 8-HQ-based
PET molecules were used as fluorescent sensors (Song et al., 2015).
Figure 11 shows two compounds that are based on 8-HQ. Compound 26
reported as a fluorescent sensor where PET process occurs from 8-HQ to borondipyrromethane (BODIPY) moieties or in the opposite direction depending on the
orbital energy levels that is modulated by the pH of the media. In acidic media, the
electrons will transfer to the lowest unoccupied molecular orbital (LUMO) of 8-HQ
(electron acceptor), while in the basic media 8-HQ works oppositely as an electron
donor from the highest unoccupied molecular orbital (HUMO). This compound can
be used in OFF-ON-OFF sensor for chemical or biological application (Chen et al.,
2011). However, González-Vera et al. (2009) reported compound 27 as a
chemosensor when binds to Mg2+ without the occurrence of PET process. The
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presence of the triazole ring in the compound extends the conjugation of the
quinoline ring, which leads to have longer excitation and emission wavelength
maxima. Having such unique fluorescent properties, compound 27 was also used to
specifically probe kinase peptides to report information about its structure and
dynamics (González-Vera et al., 2009).

Figure 11: 8-HQ derivative with electro-optical property

1.3 Urea and thiourea derivatives
Urea (28), also called carbamide, was synthesized for the first time by the
German chemist Friedrich Wöhler in 1828 by heating two inorganic compounds,
lead cyanate and ammonium hydroxide (Richard, 2009) in an attempt to synthesize
ammonium cyanate, see Figure 12 . Prior to that, urea was known to be isolated from
urine of mammals (Tóth, 1996).

Figure 12: The Wöhler synthesis of urea
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Several methods can be used to synthesize substituted urea, (Figure 13)
shows two of them, the reaction of azides in the presence of amines in the presence
of

catalyst (pd/C) under CO atmosphere (A) (Zhao et al., 2016) and the

carbonylation reaction (B) of aliphatic amines by using S,S-dimethyl dithiocarbonate
(DMDTC) as a phosgene substitute gave a substituted urea (Artuso et al., 2007).

R= alkyl, benzyl or aryl
Figure 13: Two methods (A) and (B) for synthesizing urea derivative.

Thiourea (29) can be synthesized by several methods, one of which is by
mixing amines with carbon disulfide in aqueous medium using simple condensation
system (A) (Maddani & Prabhu, 2010). Another method (B) is by reacting
isocyanides with amines and elemental sulfur to form isothiocyanates, see Figure 14
(Nguyen et al., 2014).

Figure 14:Two methods (A) and (B) for synthesizing thiourea
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1.3.1 Biological activity of urea and thiourea derivatives
Derivatives of urea and thiourea are used in several pharmaceutical
applications (Sikka, 2015). In 1903, diethylbarbituric acid 30 (Figure 15), which is
urea derivative, was used as a sleep-inducing drug and since then people started to
use barbituric acid derivatives in sleeping pills, sedatives, hypnotics, and anesthetics
(Richard, 2009). Thiourea and its derivatives also attracted the attention of medicinal
community due to their wide biological activity such as antibacterial, anticancer,
anti-ocular hypertension , and antimalarial activities (Li et al., 2017).

Figure 15: Structure of diethylbarbituric acid

1.3.1.1 Anticancer activity of urea and thiourea derivatives
Urea and thiourea derivatives have been reported to have excellent anticancer
activity (Sikka, 2015). For example, Compound 31 (Figure 16) was found to have
anticancer activity against brain cancer cells (Azeem et al., 2016). Sorafenib 32
(Figure 16) is a marketed drug used to treat advanced renal cell carcinoma and mild
hepatocellular carcinoma. Regorafenib 33 (Figure 16) is a marketed drug used to
treat metastatic colorectal and gastrointestinal stromal tumor (Lee et al., 2018).
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Figure 16: Structures for compounds 31-33 containing urea an thiourea as
anticancer drugs

Tokala et al. (2018) reported that 1,2,4-triazole-linked urea and thiourea
derivatives exhibited anti-cancer activity against breast, lung, prostate and mouse
melanoma cell lines. Compound 34 (Figure 17) illustrates significant cytotoxicity on
breast cancer cell line (Tokala et al., 2018). Aminoisoquinolinylureas derivatives
were found to have anti-cancer activity and antiproliferative activity. For example,
compound 35 was found to have high anti-proliferative activity with 0.41 µM growth
inhibitory concentration compared to the commercial sorafenib drug against several
cell lines (Cho et al., 2012) .

Figure 17: Structures for compounds 34-35 containing urea an thiourea that
have anticancer activity
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1.3.1.2 Anti-AD activity of urea and thiourea derivatives
Recently, researchers reported some urea and thiourea derivatives with antiAD properties (Ricci et al., 2017). Hroch et al. (2017) reported on some novel
thiourea containing compounds that inhibits human monoamine oxidase (MAO).
These compounds are hybrids of two AD drugs, frentizole and ladostigil. Compound
36 (Figure 18) is one of these compounds that possess potent MAO/ABAD inhibition
activity among other activities (Hroch et al., 2017). ABAD is amyloid-β binding
alcohol dehydrogenase which is cellular cofactor for promoting Aβ-mediated in
mitochondria and neurological system in transgenic AD mouse models (Valaasani et
al., 2014). Compound 37 is a pyrazinyl-urea derivative that possesses Aβ inhibition
activity with nontoxic effect on ATP production and non-cardio-toxic effect
(Elkamhawy et al., 2018).

Figure 18: Structures for compounds 36-37containing urea an thiourea that have antiAD activity

1.3.1.3 Urea and thiourea derivatives as antibiotic
Moreover, some urea and thiourea derivatives possess selective antiinflammatory, antibacterial and antifungal activity (Li et al., 2017). The antifungal
activity of the thiourea derivatives is stronger than ketoconazole which is a famous
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antifungal drug (Rodríguez et al., 2005). Compound 38 (Figure 19) shows antifungal
activity that is 2.5 time stronger than Micanazole a marketed drug. Compound 39
shows anti-inflammatory inhibition activity up to 92% at 10 M with low toxicity
(Tale et al., 2011). Compound 40 (Figure 19) shows antibacterial and antifungal
activity with the same potency as Ciprofloxacin and Miconazole drugs. Compound
41 (Figure 19) have a stronger anti-inflammatory activity than dexamethasone drug
at 10 M levels (Keche et al., 2012).

Figure 19: Structures for compounds 38-41 containing urea an thiourea that have
antibacterial and antifungal activity

Influenza is a serious disease caused by two different viruses A and B. The
classification of these viruses depends on the antigenicities of haemagglutinin and
neuraminidase. It was reported that Influenza A has haemagglutinin with sixteen
strains (H1-H16) and nine neuraminidase (N1-N9). Other serious viruses are
Coxsackie virus B4, which damage the autoimmune response in the immune system
which attacks virus-infected cells (Bason et al., 2013). Vesiculat stomatitis is a virus
that leads to a flu-like disease and respiratory syncytial virus causing mild, cold-like
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symptoms. Krishnan et al. (2014) reported two potent novel quinazoline urea
derivatives that show antiviral activity. Compound 42 (Figure 20) shows potent
replication inhibition for influenza A (H1N1), influenza A (H3N2) and influenza B at
EC50 of 0.025 μM. Compound 43 (Figure 20) shows inhibition for the replication of
Coxsackie virus B4, Vesiculat stomatitis virus and Respiratory syncytial virus at
EC50 of 0.029 μM (Krishnan et al., 2013).

Figure 20: Structures for compounds 42-43 containing urea that have antiviral activity

1.3.1.4 Other activity for urea and thiourea derivatives
Ulcer is an illness that affect both the stomach and small intestines. Stomach
ulcers occur when the protective thick layer of the stomach is damaged allowing the
digestive acids to contact with the stomach tissues causing pain (Paschou et al.,
2018). Subash et al. (2013) tested 1-benzyl-3-(p-tolyl)urea (compound 44, Figure 21)
on rats models with ulcer. Compound 44 exhibit protective effect on the models at 50
and 100 mg/kg doses and significantly reduce the total acidity and free acidity in
these models, comparable to ranitidine drug as standard (Subash et al., 2013).

Figure 21: Structure of 1-benzyl-3-(p-tolyl)urea
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Ovais et al. (2014) reported that pyrazoline substituted benzenesulfonylurea
and thiourea possessed significant blood sugar lowering activity. Compound 45 in
(Figure 22) shows a potent dual activity as anti-hyperglycaemic and aldose reductase
inhibition (Ovais et al., 2014).

Figure 22: Structure for thiourea containing compound with sugar lowering
activity

1.4 Piperazine derivative
Piperazine 46 is six carbon membered ring with two nitrogens in opposite
positions to each other (Arbo et al., 2012). Piperazine can be synthesized by heating
diethylenetriamine with the help of a catalyst (Raney nickel). The most suitable
temperature is 150℃ or above, see Figure 23 (Martin and Martell, 1948).

Figure 23: Synthesis of piperazine
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1.4.1 Biological activities of piperazine derivatives
Piperazine 46 itself is a drug used as treatment for many diseases such as
ascariasis, enterobiasis and partial intestinal obstruction. Piperazine has drug-like
properties because it can easily form multiple hydrogen or ionic bonds with low
toxicity. Many drugs containing piperzine are available in the market including
delavirdine, which is used for HIV-1 infection treatment as antiretroviral agents
(Guan et al., 2008), urapidil 47 (Figure 24), which is used to manage hypertension
(Waszkielewicz et al., 2016). Moreover, piperzine moiety is also present in
nefazodone 48 (Figure 24), which is used as antidepressant medicine, and buspirone,
which have anxiolytic activities (Silva et al., 2018). Also, it was reported that Nsubstituted piperazine derivatives show a variety of biological activities such as
antimicrobial, anticancer, antifungal, and tuberculostatic activities (Wang et al.,
2016).

Figure 24: Structure of urapidil and nefazodone
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1.4.1.1 Anticancer activities of piperazine derivatives
Many novel compounds containing

piprazine were shown to have anti-

cancer activity (Aouad et al., 2018). For example, compound 49 (Figure 25) which
contains dithiocarbamates and piperazine, exhibits a good inhibitory activity against
human cervical carcinoma and liver cancer cell lines (Wei et al., 2018). Compound
50 (Figure 25) was reported to have anti-proliferative activity against pancreatic,
cervical and breast cancer (Banu et al., 2017).

Figure 25: Structures for compounds 49-50 containing piperazine that have
anticancer activity

1.4.1.2 Anti-AD activities of piperazine derivatives
Figure 26 shows two compounds with anti-AD activity. Compound 51 was
found to be a multi targeting compound that have Aβ aggregation, AChE and BuChE
inhibition activity. Also, it has a radical scavenging activity (Meena et al., 2015).
Compound 52 is also reported to have AD treatment characteristic such as effective
AChE inhibitions, selectivity over BChE and high free radical scavenger activity.
Youssef et al. (2018) suggested that compound 52 could be template for further
study as anti-AD (Youssef et al., 2018).
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Figure 26: Structures for compounds 51-52 containing piperazine that have
anti-AD activity

1.4.1.3 Antiviral activities of piperazine derivatives
Compound 53 (Figure 27) is a berberine-piperazine derivatives that have
anti-viral activity against influenza virus and shows maximum neuraminidase
inhibition with low cytotoxicity level (Enkhtaivan et al., 2018). Compound 54 is also
an anti-virus agent used for norovirus, which is a potent contagious virus causing
vomiting and diarrhea (Arbo et al., 2012).

Figure 27: Structures for compounds 53-54 containing piperazine that have anti-viral
activity

24
1.5 Research plan
Based on the previous discussion of rich spectrum of bioactivity of 8-HQ and
its derivatives, piperazine derivatives and urea/ thiourea derivatives given in this
chapter, we designed a series of compounds as outlined in Figure 28.

Figure 28: General synthesis of hydroxyquinoline-carbothioamide (thiourea) (61a-i)
and hydroxyquinoline –carboxamide (urea) derivatives (62a-d)

Table 1: Compounds (61a-i) and (62a-d) substitution
R

H

4-CH3

4-OCH3

4-Cl

4-NO2

2-F

3-F

4-F

4-CF3

X=S

61a

61b

61c

61d

61e

61f

61g

61h

61i

62a

62b

62c

62d

-

-

-

-

X=O -

These compounds are designed so that they contain several substituents of
aryl urea and thiourea functionalities. It is expected that the different substituents
with two groups of electron donating such as (OCH3 and CH3) and electron
withdrawing groups such as (F, Cl, CF3 and NO2) are expected to affect the
bioactivity of these compounds (Table 1). This is the project hypothesis.
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Chapter 2: Material and Methods

2.1 Chemistry experimental
General Methods: FT-IR spectra measured in a Thermo Nicolet Nexus 470
FT-IR spectrophotometer (USA). 1H NMR and
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C NMR spectra recorded at room

temperature using Varian-400 MHz (USA), CDCl3 (400 MHz) or DMSO-d6 (100
MHz) used as internal references with solvent peaks at [CDCl3: 7.26, 77.2 ppm and
DMSO-d6 2.50 and 39.57 ppm]. The chemical shifts assign corresponding to a
standard NMR experiments (1H,
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C, 1H-1H COSY, 1H-13C HSQC, HMBC). Silica

F254 was used for TLC analyses and UV light at 254 nm was used for detection.
Open capillary tube (Sanyo Gallenkamp MPD 350-BM 3.5 Melting Point apparatus)
(UK) was used to determine melting points (MP). Chemicals and reagents were
purchased from Sigma Aldrich Chemical Co. and ACROS ORGANICS, USA. No
further purification was needed for all chemicals and reagents received.
Synthesis of key intermediate (58):

Figure 29: Synthesis scheme of key intermediate 58

Figure 29 shows general scheme of synthesizing the key intermediate (5piperazineomethyl-8-hydroxyquinoline 58) by first synthisizing 5-chloromethyl-8quinolinol hydrochloride 55 from 8-HQ.
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Preparation of 5-chloromethyl-8-quinolinol hydrochloride (55):

A mixture of (5.84 g, 70.0 mmol) solid 8-hydroxyquine,50 ml conc. HCl and 6.4 ml
formaldehyde was treated with 1.05 g zinc chloride with overnight stirring. Then the
mixture filtered, washed with acetone and dried to give 7.94g 5-chloromethyl-8quinolinol hydrochloride as yellow solid (86%).

1

H NMR (400 MHz, Deuterium

Oxide) δ 9.06 (dd, J = 8.7, 1.4 Hz, 1H), 8.81 (dd, J = 5.4, 1.4 Hz, 1H), 7.90 (dd, J =
8.7, 5.4 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.18 (d, J = 8.0 Hz, 1H), 4.87 (d, J = 0.6
Hz, 2H). 13C NMR (100 MHz, D2O) δ 145.96, 143.02, 141.86, 129.99, 127.84,
127.36, 127.15, 121.70, 115.05, 59.77.
Synthesis of tert-butyl 4-((8-hydroxyquinolin-5-yl)methyl)piperazine-1-carboxylate
(57):

Mixture of (6g,1eq) 5-chloromethyl-8-quinolinol hydrochloride 55, (4.86g, 1eq) Ntert-butoxycarbonyl piperazine and (9.8 ml, 2.64 eq) triethylamine (TEA) was stirred
in 200 ml THF overnight at room temperature. After the reaction reach completion
the THF was evaporated and the solid was extracted with ethyl acetate (3x 250 ml).
The organic phase was collected and dried over anhydrous sodium sulfate, filtered
and evaporated to give the desired product as white solid (m = 8.8 g, 0.0256 mol,
97%). 1H NMR (400 MHz, Chloroform-d) δ 8.78 (dd, J = 4.2, 1.6 Hz, 1H), 8.66
(ddd, J = 8.5, 1.6, 0.7 Hz, 1H, CH), 7.47 (dd, J = 8.6, 4.2 Hz, 1H, CH), 7.33 (d, J =

27
7.7 Hz, 1H, CH), 7.07 (d, J = 7.7 Hz, 1H, CH), 3.81 (s, 2H, -CH2-), 3.38 (s, 4H, 2xCH2-), 2.41 (s, 4H, 2x-CH2-), 1.44 (s, 9H, 3xCH3).
Synthesis of 5-piperazineomethyl-8-hydroxyquinoline (58):

0.15 g of 5-(N’-Boc-piperazineomethyl)-8-hydroxyquinoline was dissolved in dry
4.5 ml of dioxane and 3ml of 4 M HCl in dioxane was added. The mixture was
stirred for 2 hours at room temperature. The dioxane was removed under vacuum to
obtain the 0.15 g product as yellow powder (98%). 1H NMR (400 MHz, D2O) δ 9.26
(dd, J = 8.8, 1.3 Hz, 1H), 8.96 (dd, J = 5.5, 1.3 Hz, 1H), 8.06 (dd, J = 8.8, 5.4 Hz,
1H), 7.87 (d, J = 8.2 Hz, 1H), 7.38 (dd, J = 8.1, 1.2 Hz, 1H), 4.84 (d, J = 1.2 Hz, 2H),
3.50 (dd, J = 4.92, 7.1, 3.7 Hz, 8H).
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C NMR (100 MHz, D2O) δ 149.7, 143.1,

143.0, 136.5, 129.8, 129.3, 122.9, 115.6,115.5, 55.9, 48.2, 40.7.
General synthesis of hydroxyquinoline-carbothioamide (61a-i) and hydroxyquinoline
-carboxamide derivatives (62a-d):

To a stirred solution of 5-piperazineomethyl-8-hydroxyquinoline 58 in dry
acetonitrile (10 mL), was added excess triethylamine (460 µL, 3.5 eq) and the
corresponding isothiocyanatobenzene 59 or isocyanatobenzene 60 (0.9 eq). The
mixture was stirred at room temperature for 1.5- 2h and the solvent was removed
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under vacuum. The residue was extracted by addition of water (20 mL ) and ethyl
acetate (3x 20 mL). Aanhydrous sodium sulfate was added to the organic layer,
filtered and then the ethyl acetate was evaporated under vacuum. Crystallization of
the crude in ethanol gave the desired compounds.
4-((8-hydroxyquinolin-5-yl)methyl)-N-phenylpiperazine-1-carbothioamide (61a):

Off-White solid, (0.25 g, 67%); Rf = 0.3 (Ethyl acetate); mp 205-207°C; IR (KBr,
cm-1) 1535 (SO), 3233 (NH), 3322 (OH); 1H NMR (400 MHz, DMSO-d6) δ 9.71 (s,
1H), 9.26 (s, 1H), 8.85 (dd, J = 4.2, 1.6 Hz, 1H), 8.67 (dd, J = 8.6, 1.7 Hz, 1H), 7.58
(dd, J = 8.6, 4.1 Hz, 1H), 7.35 (d, J = 7.8 Hz, 1H), 7.26 (d, J = 6.2 Hz, 4H), 7.07 (dd,
J = 5.8, 3.2 Hz, 1H), 6.99 (d, J = 7.7 Hz, 1H), 3.82 (d, J = 4.7 Hz, 6H), 2.48 (q, J =
1.9 Hz, 4H). 13C NMR (100 MHz, DMSO-d6) δ 181.6 , 153.4, 148.3, 141.5, 139.3,
134.3, 129.5, 128.5, 128.4, 126.0, 124.7, 124.1, 122.0, 110.4, 59.5, 52.8, 48.5.
4-((8-hydroxyquinolin-5-yl)methyl)-N-(p-tolyl)piperazine-1-carbothioamide (61b):

Off-White solid, (0.25 g, 64%); Rf = 0.4 (Ethyl acetate); mp 193-195°C IR (KBr, cm1

) 1530 (SO), 3211 (NH), 3402 (OH); 1H NMR (400 MHz, DMSO-d6) δ 9.74 (s, 1H),

9.20 (s, 1H), 8.84 (dd, J = 4.2, 1.5 Hz, 1H), 8.66 (dd, J = 8.6, 1.6 Hz, 1H), 7.57 (dd, J
= 8.6, 4.1 Hz, 1H), 7.34 (d, J = 7.8 Hz, 1H), 7.12 (d, J = 8.1 Hz, 2H), 7.06 (d, J = 8.1
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Hz, 2H), 6.99 (d, J = 7.7 Hz, 1H), 5.82 (d, J = 4.8 Hz, 2H), 3.80 (s, 4H), 2.44 (t, J =
4.9 Hz, 4H), 2.24 (s, 3H).
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C NMR (100 MHz, DMSO-d6) δ 181.7, 153.4, 148.3,

139.3, 138.9, 134.2, 133.9, 29.5, 128.9, 128.3, 125.9, 124.1, 122.0, 110.4, 59.5, 52.8,
48.4, 21.0.
4-((8-hydroxyquinolin-5-yl)methyl)-N-(4-methoxyphenyl)piperazine-1carbothioamide (61c):

White solid, (0.32 g, 78%); Rf = 0.4 (Ethyl acetate); mp 190-192°C; IR (KBr, cm-1)
1531 (SO), 3231 (NH), 3436 (OH); 1H NMR (400 MHz, DMSO-d6) δ 9.75 (s, 1H),
9.14 (s, 1H), 8.84 (dd, J = 4.2, 1.6 Hz, 1H), 8.66 (dd, J = 8.6, 1.6 Hz, 1H), 7.58 (dd, J
= 8.6, 4.1 Hz, 1H), 7.35 (d, J = 7.8 Hz, 1H), 7.16 – 7.06 (m, 2H), 6.99 (d, J = 7.7 Hz,
1H), 6.91 – 6.77 (m, 2H), 3.81 (s, 6H), 3.71 (s, 3H), 2.43 (d, J = 5.4 Hz, 4H).
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C

NMR (100 MHz, DMSO-d6) δ 181.8, 156.9, 150.5, 148.3, 139.3, 134.3, 129.2,
128.3, 127.8, 123.9, 122.0, 117.0, 113.6, 110.4, 59.5, 55.6, 52.8, 48.3.
N-(4-chlorophenyl)-4-((8-hydroxyquinolin-5-yl)methyl)piperazine-1-carbothioamide
(58d):

Off-White solid, (0.25 g, 62%); Rf = 0.2 (Ethyl acetate); mp 224-226°C IR (KBr, cm1

) 1528 (CS), 3320 (NH), 3436 (OH); 1H NMR (400 MHz, DMSO-d6) δ 9.74 (s, 1H),

9.34 (s, 1H), 8.84 (dd, J = 4.1, 1.6 Hz, 1H), 8.66 (dd, J = 8.6, 1.6 Hz, 1H), 7.58 (dd, J
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= 8.5, 4.1 Hz, 1H), 7.34 (d, J = 7.7 Hz, 1H), 7.33 – 7.24 (m, 4H), 6.99 (d, J = 7.7 Hz,
1H), 3.82 (d, J = 5.8 Hz, 6H), 2.45 (d, J = 5.3 Hz, 4H). 13C NMR (100 MHz, DMSOd6) δ 181.4, 153.4, 148.3, 140.5, 139.3, 134.2, 129.6, 128.6, 128.3, 128.3, 127.2,
124.1, 122.0, 110.4, 59.5, 52.7, 48.5.
4-((8-hydroxyquinolin-5-yl)methyl)-N-(4-nitrophenyl)piperazine-1-carbothioamide
(61e):

Yellow solid, (0.25 g, 60%); Rf = 0.25 (Ethyl acetate); mp 170-172°C; IR (KBr, cm1

) 1530 (CS), 3150 (NH), 3399 (OH); 1H NMR (400 MHz, DMSO-d6) δ 9.82 (s, 1H),

8.85 (d, J = 3.9 Hz, 1H), 8.67 (d, J = 8.5 Hz, 1H), 8.27 – 8.05 (m, 2H), 7.66 – 7.58
(m, 1H), 7.56 (d, J = 8.8 Hz, 2H), 7.35 (d, J = 7.8 Hz, 1H), 7.00 (d, J = 7.7 Hz, 1H),
3.84 (d, J = 12.2 Hz, 1H), 3.82 (d, J = 5.8 Hz, 6H), 2.45 (d, J = 5.3 Hz, 4H).
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C

NMR (100 MHz, DMSO-d6) δ 180.8, 153.5, 148.3, 148.3, 142.3, 139.3, 134.2,
129.6, 128.3, 124.4, 123.1, 122.8, 122.0, 110.5, 59.3, 52.7, 49.1.
N-(2-fluorophenyl)-4-((8-hydroxyquinolin-5-yl)methyl)piperazine-1-carbothioamide
(61f):

Beige solid, (0.25 g, 64%); Rf = 0.25 (Ethyl acetate); mp 161-163°C; IR (KBr, cm-1)
1532 (CS), 3164 (NH), 3304 (OH); 1H NMR (400 MHz, DMSO-d6) δ 9.74 (br s,
1H), 9.10 (s, 1H), 8.85 (dd, J = 4.2, 1.6 Hz, 1H), 8.67 (dd, J = 8.6, 1.6 Hz, 1H), 7.59
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(dd, J = 8.6, 4.1 Hz, 1H), 7.36 (d, J = 7.8 Hz, 1H), 7.28 – 7.07 (m, 5H), 3.83 (d, J =
8.8 Hz, 6H), 2.46 (s, 4H).
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C NMR (100 MHz, DMSO-d6) δ 182.2, 159.0, 156.6,

153.4, 148.3, 139.3, 134.2, 130.5, 129.6, 129.3, 129.2, 128.3, 128.1, 128.0, 124.5,
124.4, 122.0, 116.2, 116.0, 110.5, 59.5, 52.7, 48.4
N-(3-fluorophenyl)-4-((8-hydroxyquinolin-5-yl)methyl)piperazine-1-carbothioamide
(61g):

White solid, (0.29 g, 74%); Rf = 0.35 (Ethyl acetate); mp 206-208°C IR (KBr, cm-1)
1537 (CS), 3225(NH), 3321 (OH); 1H NMR (400 MHz, DMSO-d6) δ 9.74 (s, 1H),
9.39 (s, 1H), 8.84 (dd, J = 4.1, 1.6 Hz, 1H), 8.66 (dd, J = 8.6, 1.6 Hz, 1H), 7.58 (dd, J
= 8.6, 4.1 Hz, 1H), 7.35 (d, J = 7.8 Hz, 1H), 7.28 (td, J = 8.2, 6.8 Hz, 1H), 7.20 (t, J
= 2.3 Hz, 1H), 7.17 (t, J = 2.3 Hz, 1H), 7.10 (dd, J = 1.9, 0.9 Hz, 1H), 7.08 (dd, J =
2.1, 0.9 Hz, 1H), 6.99 (d, J = 7.7 Hz, 1H), 6.93 – 6.84 (m, 1H), 3.82 (d, J = 7.7 Hz,
4H), 2.45 (d, J = 5.2 Hz, 4H). 13C NMR (100 MHz, DMSO-d6) δ 181.3, 163.3, 160.9,
153.4, 148.3, 143.4, 143.3, 139.3, 134.2, 129.9, 129.8, 129.6, 128.3, 124.1, 122.0,
120.8, 120.8, 112.0, 111.8, 111.1, 110.8, 110.5, 59.5, 52.7, 48.6.
N-(4-fluorophenyl)-4-((8-hydroxyquinolin-5-yl)methyl)piperazine-1-carbothioamide
(61h):
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White solid, (0.35 g, 90%); Rf = 0.2 (Ethyl acetate); mp 235-237°C; IR (KBr, cm-1)
1538 (CS), 3241(NH), 3321 (OH); 1H NMR (400 MHz, DMSO-d6) δ 9.76 (s, 1H),
9.29 (s, 1H), 8.83 (d, J = 4.1 Hz, 1H), 8.65 (d, J = 8.6 Hz, 1H), 7.56 (dd, J = 8.6, 4.1
Hz, 1H), 7.40 – 7.17 (m, 3H), 7.09 (t, J = 8.6 Hz, 2H), 6.99 (d, J = 7.7 Hz, 1H), 3.83
(s, 4H), 3.79 (s, 2H), 2.44 (t, J = 4.7 Hz, 4H).13C NMR (100 MHz, DMSO) δ 181.7,
160.8, 158.4, 153.4, 148.3, 139.3, 137.8, 137.8, 134.2, 129.5, 128.3, 128.1, 128.0,
124.1, 122.0, 115.1, 114.9, 110.4, 59.5, 52.7, 48.4.
4-((8-hydroxyquinolin-5-yl)methyl)-N-(4-(trifluoromethyl)phenyl)piperazine-1carbothioamide (61i):

White solid, (0.40 g, 91 %); Rf = 0.4 (Ethyl acetate); mp 191-193; IR (KBr, cm-1)
1535 (CS), 3172 (NH), 3311 (OH); 1H NMR (400 MHz, DMSO-d6) δ 9.75 (s, 1H),
9.56 (s, 1H), 8.84 (dd, J = 4.2, 1.6 Hz, 1H), 8.66 (dd, J = 8.6, 1.6 Hz, 1H), 7.64 –
7.55 (m, 3H), 7.52 – 7.45 (m, 2H), 7.35 (d, J = 7.8 Hz, 1H), 6.99 (d, J = 7.7 Hz, 1H),
3.84 (m, 4H), 3.81 (s, 2H), 2.46 (m, 4H).
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C NMR (100 MHz, DMSO-d6) δ 181.3,

15.4, 148.2, 148.2, 145.4, 139.3, 134.2, 129.5, 128.3, 126.3, 125.6, 125.5, 124.5,
124.4, 123.9, 123.6, 122.0, 110.4, 59.5, 52.7, 48.8.
4-((8-hydroxyquinolin-5-yl)methyl)-N-(p-tolyl)piperazine-1-carboxamide (62a):
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White solid, (0.25 g, 66%); Rf = 0.3 (Ethyl acetate); mp 168-170°C; IR (KBr, cm-1)
1637 (CO), 3337(NH), 3435 (OH); 1H NMR (400 MHz, DMSO-d6) δ 9.72 (s, 1H),
8.84 (dd, J = 4.1, 1.6 Hz, 1H), 8.66 (dd, J = 8.6, 1.7 Hz, 1H), 8.35 (s, 1H), 7.58 (dd, J
= 8.6, 4.1 Hz, 1H), 7.34 (d, J = 7.7 Hz, 1H), 7.29 (d, J = 8.4 Hz, 2H), 6.99 (dd, J =
7.9, 5.8 Hz, 3H), 3.78 (s, 2H), 3.48 (4H), 2.38 (t, J = 5.1 Hz, 4H), 2.19 (s, 3H, CH3).
4-((8-hydroxyquinolin-5-yl)methyl)-N-(4-methoxyphenyl)piperazine-1-carboxamide
(62b):

White solid, (0.26 g, 68%); Rf = 0.3 (Ethyl acetate); mp 152-153°C; IR (KBr, cm-1)
1638 (CO), 3259 (NH), 3434 (OH); 1H NMR (400 MHz, DMSO-d6) δ 8.84 (dd, J =
4.2, 1.6 Hz, 1H), 8.66 (dd, J = 4.2, 1.6 Hz, 1H), 8.63 (dd, J = 8.6, 1.6 Hz, 1H), 8.31
(s, 1H), 7.56 (dd, J = 8.6, 4.1 Hz, 1H), 7.33 (d, J = 7.8 Hz, 1H), 7.28 (d, J = 9.0 Hz,
2H), 6.98 (d, J = 7.7 Hz, 1H), 6.78 (d, J = 9.0 Hz, 2H), 3.77 (s, 2H), 3.66 (s, 3H),
3.34 (t, J = 4.8 Hz, 4H), 2.38 (t, J = 4.9 Hz, 4H). 13C NMR (100 MHz, DMSO-d6) δ
170.9, 155.6, 154.9, 153.4, 148.3, 139.3, 134.2, 133.9, 129.5, 128.3, 124.2, 122.02,
113.9, 110.4, 60.2, 55.7, 53.0, 44.1.
N-(4-chlorophenyl)-4-((8-hydroxyquinolin-5-yl)methyl)piperazine-1-carboxamide
(62c):
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Off-White solid, (0.31 g, 80%); Rf = 0.4 (Ethyl acetate); mp 187-191°C; IR (KBr,
cm-1) 1642 (CO), 3259 (NH), 3434 (OH); 1H NMR (400 MHz, DMSO-d6) δ 9.74 (s,
1H), 8.84 (dd, J = 4.1, 1.6 Hz, 1H), 8.65 (dd, J = 8.6, 1.7 Hz, 1H), 8.61 (s, 1H), 7.57
(dd, J = 8.6, 4.1 Hz, 1H), 7.51 – 7.42 (m, 2H), 7.32 (d, J = 7.8 Hz, 1H), 7.28 – 7.20
(m, 2H), 6.99 (d, J = 7.7 Hz, 1H), 3.77 (s, 2H), 3.39 (t, J = 4.9 Hz, 4H), 2.39 (t, J =
4.9 Hz, 4H).
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C NMR (100 MHz, DMSO-d6) δ 155.1, 153.4, 148.3, 140.0, 139.3,

134.2, 129.5, 128.6, 128.3, 125.7, 124.2, 121.9, 121.4, 110.4, 59.9, 52.9, 44.2.
4-((8-hydroxyquinolin-5-yl)methyl)-N-(4-nitrophenyl)piperazine-1-carboxamide
(62d):

White solid, (0.24g, 60%); Rf = 0.25 (Ethyl acetate); mp 200-202°C; IR (KBr, cm-1)
1659 (CO), 3209 (NH), 3300 (OH); 1H NMR (400 MHz, DMSO-d6) δ 9.75 (s, 1H),
9.21 (s, 1H), 8.84 (dd, J = 4.1, 1.6 Hz, 1H), 8.65 (dd, J = 8.6, 1.6 Hz, 1H), 8.22 –
8.04 (m, 2H), 7.84 – 7.64 (m, 2H), 7.57 (dd, J = 8.6, 4.1 Hz, 1H), 7.33 (d, J = 7.8 Hz,
1H), 6.99 (d, J = 7.7 Hz, 1H), 3.79 (s, 2H), 3.42 (d, J = 5.3 Hz, 4H), 2.41 (t, J = 5.0
Hz, 4H). 13C NMR (100 MHz, DMSO-d6) δ 154.4,153.5 148.3, 147.9, 141.2, 139.3,
134.3, 129.5, 128.3, 125.2,124.1 121.9, 118.7, 110.4, 59.8, 52.9, 44.4.

2.2 Biological activities experimental
2.2.1 Antibacterial activity
Compounds (61a-i) and (62a-d) were dissolved in dimethyl sulfoxide (SigmaAldrich, France) to a concentration of stock 2500 µM. The solution in Mueller
Hinton Broth (Himedia Laboratories, Mumbai, India) was diluted with nine step
resulting in concentrations of 1250, 625, 312.5, 156.25, 78.125, 39.1, 19.5, 9.8 and
4.9 µM of each compounds. From each solution 1 ml was added to 24 ml of molten
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Mueller Hinton Agar (MHA) (MAST, Merseyside, UK) to prepare MHA containing
100, 50, 25, 12.5, 6.25, 3.125, 1.6, 0.8, 0.4 and 0.2 µM of each compounds tested.
Control antibiotics: ciprofloxacin, cephalexine, cefotaxime and sodium azide were
diluted using the same method. For control, plates containing DMSO corresponding
to the concentration of each dilutions .
The compounds antibacterial activity tested on 6 type of pathogenic bacteria:
Esherichia coli (ATCC25922), Pseudomonas aeruginosa (ATCC27853), Salmonella
entericasv. Braenderup H9812 (ATCC BAA-664), Klebsiella pneumoniae
(ATCC700603), Staphylococcus aureus (ATCC25923) and Enterococcus fecalis
(ATCC29212).
Around 104 CFU/ml were prepared in phosphate buffered saline (10 µl
drop), around 100 bacterial cell was placed on the MHA plates surface containing the
above chemical compounds described concentrations. For growth control, A MHA
plate without chemicals was used in each experiment. Plates were pleaced in
incubator for 18 hours at 37°C temperature in a humidified atmosphere of ambient
air. The result was recorded after incubation and bacterial growth.

2.2.2 Antifungal activity
The compounds (61a-i) and (62a-d) were evaluated in-vitro on the mycelial
growth of the following four selected fungi: Fusarium solani, Neocystalidium
dimediatum, Botrytis cinerea, and Thielaviopsis punctulata. The 13 compounds were
dissolved in DMSO with 100 µM concentration. To prevent the bacterial growth,
1mL of the Chloramphenicol 50 mg/ml antibiotic was added in the potato dextrose
agar medium (PDA), autoclaved and poured into sterile petri dishes. Then the plates
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were incubated at 27ºC temperature for 7 days. sterile cork-borer was used to made
holes with 10-mm diameter in the PDA plate (each petri plate dish has 4 holes).
Then 0.2 mL of each compound was injected in each hole, and placed for 1 hour in
the refrigerator (4ºC).
The tested pathogens were placed in the middle PDA petri-dish plate
containing the compounds by a sterile cork-borer with 5-mm in diameter. All plates
were incubated for 7 days at 27ºC temperature. The result was recorded by
measuring the inhibition zone in mm for compounds.

2.3 Metal chelation experimental
CARY-50 instrument (Agilent, Santa Clara, CA, USA) was used to measure
the UV-visible absorption spectra between (200-800 nm) at room temperature with
Scan Software version 3.00(182) Operator and dual beam mode using matched
quartz cuvettes of 1 cm path-length. Complex formation between 8-HQ compounds
and metal ions (Cu , Zn and Fe) was performed by gradual addition of metal ions
solution stock (1.78x10-3 M) of copper (II) sulfate , zinc (II) acetate and iron (III)
chloride hexahydrate to a fixed concentration 2.39x10-5M 8-HQ compounds until
saturation was reached.

2.4 Photophysical experimental
Steady-state and time resolved fluorescence measurements of 8HQ
compounds in the solid state, utilizing a solid sample holder with front-face
geometry, were carried out using LifeSpecII spectrometer (Edinburgh, Kirkton
Campus, UK) that based on time-correlated single-photon counting (TCSPC) method
with excitation at 375 nm using Edinburgh picosecond diode laser (EPL-375) with a
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repetition rate at 20 MHz and instrument function at 30 ps. The detector was a highspeed red-sensitive PMT (H5773-04, Hamamastu Phtonics K.K, Hamamastu, Japan).
Emission decay were measured for each 8-HQ compound every 5 nm over
the entire emission spectrum with a dwell time of 10 s at each wavelength. The data
were globally fitted to a 3-exponential model function convoluted with instrument
response function (IRF) of ~30 ps. The time-resolved data were specifically analyzed
using Edinburgh FAST software in which decay-associated spectra (DAS) were
constructed from the extracted intensity-contribution fraction (fi) calculated from the
pre-exponential amplitudes (Bi), as follows:
∑

(1)
(2)

∑

The denominator sum is over all the decay times and amplitudes. The mean
decay time (average lifetime) were calculated at 480 nm (emission of 8-HQ moiety)
by the following equation:
̅

∑

(3)
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Chapter 3: Results and Discussion

3.1 Overview of synthesis
A series of hydroxyquinoline-carbothioamide (thiourea) (61a-i) and
hydroxyquinoline –carboxamide (urea) derivatives (62a-d) were synthesized as
outlined in Figure 28 (page 24). These compounds are designed so that they contain
several substation of aryl urea (carboxamide) and thiourea (carbothioamide )
functionalities, see Table 1 (Page 24). It is expected that the different factors such as
substituents electronegativity with two groups of electron donating such as (OCH3
and CH3) and electron withdrawing groups such as (F, Cl, CF3 and NO2) and
substituents position such as fluorine in compound (61f, 61g and 61h) expected to
affect the bioactivity of these compounds. This is a hypothesis to be tested in the
project.
The

project

started

with

synthesizing

the

key

intermediate

(5-

piperazineomethyl-8-hydroxyquinoline 58) by first synthisizing 5-chloromethyl-8quinolinol hydrochloride 55 from 8-HQ. Then, synthisizing tert-butyl 4-((8hydroxyquinolin-5-yl)methyl)piperazine-1 carboxylate 57 from compound 55. After
that, removing the protected group to have the key intermediate. Finally, reacting the
key intermediate with vared substituted isocyanate and isothiosyanate to preduce our
targeted compound (61a-i) and (62a-d).

Synthesis of 5-chloromethyl-8-quinolinol hydrochloride (55):
The synthesis of 5-chloromethyl-8-quinolinol hydrochloride 55 been
described in literature (Xiao et al., 2015). In this reaction, the OH group in 8-HQ is a
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strongly activating group toward electrophilic aromatic substitution reaction
directing substituents to the ortho and para positions. The carbon number 5 attacks
the carbonyl in the formaldehyde and the oxygen protonated to be OH which
replaced with Cl from the HCl, see Figure 30. The reaction was repeated several
times with different conditions to enhance the yield from 63% to 86% (published
yield = 90%).

Figure 30: Suggested mechanism for synthesis 5-chloromethyl-8-quinolinol
hydrochloride

Synthesis of tert-butyl 4-((8-hydroxyquinolin-5-yl)methyl)piperazine-1 carboxylate:
The original plan for the synthesis of key intermediate 58 was by the reaction
of 55 with piperazine 63 (Figure 31). However, several attempts gave only a very
small amount of the desired product 58 and the major product was the dimer 5,5'(piperazine-1,4-diylbis(methylene))bis(quinolin-8-ol) 64 which was verified by 1H
NMR data.
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Figure 31: The reaction of compound 55 with piperazine 63

Therefore, compound 56 (N-Boc piperazine) or (tert-Butyl piperazine-1carboxylate) was used instead piperazine 63 as outline in figure 32:

Figure 32: The reaction of compound 55 with Boc-piperazine 56

The N-Boc protected piperazine-hydroxyquinoline 57 was obtained from 5chloromethyl-8-quinoline 55 by nucleophilic substitution with the N-Boc in
piperazine 56, see Figure 33. This reaction was done with two different solvent and
bases. DIPMA or TIPEA in chloroform needed complicated extraction and
purification by column chromatography using eluent of increasing polarity
(recrystallization was not effective). Using triethylamine in THF was more efficient
than the DIPMA or TIPEA in chloroform with a shorter reaction time and easier
workup (extraction with ethyl acetate and water). Better yields (97%) were obtained
with no need for further purification.
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Figure 33: Suggested mechanism for synthesis compounds 57 & 58

The removal of

the Boc protecting group from compound 57 in

dichloromethane with trifluoroacetic acid (TFA) did not give the intended product 58
as indicated by 1H NMR data. However, this was achieved by using HCl in 1,4dioxane and 58 was obtained with 98% yields and structure was confirmed by 1H
NMR and 13C NMR, see Figure 34.

Figure 34: The reaction of compound 55 with Boc-piperazine 56
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Synthesis of hydroxyquinoline-carbothioamide (61a-i) and hydroxyquinoline carboxamide derivatives (62a-d):

Figure 35: Suggested mechanism for Compounds (61a-i) and (62a-d)

Compounds (61a-i) and (62a-d) were synthesized by the reaction of 58 with
aryl isothiocyanate 59 and aryl isocyanate 62 using TEA as base (Figure 35) . The
yield range of these compounds was (60%-80%) for urea and (60%-91%) for
thiourea. The slightly low yield can be explained by the times of recrystallization.
Several solvent was used for the recrystallization and the most suitable one was the
ethyl acetate. The reaction time of urea compounds (62a-62d) was slightly shorter
than

thiourea compounds (61a-61i) and that can be explained by the

electronegativity of oxygen in urea which made it more reactive than thiourea
derivatives. Compounds (61f, 61g, 61h and 61i) which have fluorine in there
structure, have high affinity for water and they required salt out effect to get the
maximum amount of the crude.
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The structures of all newly synthesized compounds were characterized by IR,
1

H NMR and

13

C NMR. The 1H-NMR spectra of compounds (61a-i) & (62a-d)

showed the ethyl protons signals of piperazine at around 2.48 ppm and around 3.84
ppm. The 8-HQ proton signals appears at around 9.71 ppm as a singlet for the OH
group and the CH appears at around 7.0 ppm and 7.3 ppm for the phenyl ring. The 8HQ pyridine ring shows 3 signals for the CH at around 7.5 ppm, 8.6 ppm & 8.8 ppm.
The NH proton in the urea and thiourea appears at around 9.26 ppm and the benzene
rings shows 3 signals for the CH at around 7.0 ppm, 7.2 ppm & 7.3 ppm. The methyl
group in compounds (61b & 62a) appears upfield at around 2.4 ppm compared to the
CH3 in compounds (61c & 62b ) with methoxy group which appears at around 3.8
ppm.
The 13C-NMR spectra shows the piperazine carbons upfield at 48.5 ppm and
52.75 ppm. The methylene group that connect the piperazine and the 8-HQ ring
carbons signal appears at around 59.6 ppm. The thiourea carbon signal appears at
181.6 ppm which is more down field than the urea carbon signal at

155 ppm. The

methyl group in compounds (61b & 62a) appears upfield at 20.97 ppm. The CH3 of
the methoxy group in compounds (61c & 62b ) appears at 55 ppm. The carbon signal
of compound 61i (CF3) appears at 124 ppm.
The IR spectra of compounds (61a-i) & (62a-d) exhibit a broad O-H band
near 3400 cm-1.The formation of the thiourea is also confirmed by intense band
around 1530 cm-1which corresponds to C=S stretching bands. The urea formation
was confirmed by the band at 1650 cm-1.
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3.2 Biological activities
3.2.1 Antibacterial activity
The antibacterial activity of compounds (61a-i) and (62a-d) was tested
against 6 type of pathogenic bacteria: Escherichia coli (25922), Pseudomonas
aeruginosa (27853), Salmonella (H9812), Klebsiella pneumonia (700603),
Staphylococcus aureus (25923) and

Enterococcus (29212). E. coli Found in a

contaminated water or food causing several symptoms such as diarrhea, abdominal
pain and vomiting. P. aeruginosa is a life-threatening bacteria, one of its symptoms
is pneumonia (Smet et al., 2017). Salmonella found in contaminated water ,food or
carrier animals excrements. Also, unclean kitchens is an environment of Salmonella
bacteria. The most common Salmonella symptoms are diarrhea, abdominal pain
vomiting and fever (Su and Chiu, 2007). K. pneumonia normally founds on the
human

mouth

flora,

intestines

and

skin.

When

K.

pneumonia

enters

the respiratory system it cause pneumonia or blood infection when enters the
bloodstream (Yigit et al., 2001). S. aureus normally founds on the human respiratory
system and skin. S. aureus can cause food poisoning, skin infection or Bone
infection. Enterococcus cause urinary tract infections, diverticulitis or bacteremia
(Ike, 2016).
The antibacterial activity study was done on these types of bacteria because
they develop resistance against the antibiotics. Therefore, they need continuous
development of new drugs. Table 2 shows the concentration of the compounds at
which the bacteria grow in.
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Table 2: The concentration of the compounds (61a-i) and (62a-d) at which the 6 type
of chosen pathogenic bacteria grow in
E.coli P.aereginosa Salmonella K.pneumoniae S.aureus Enteroco-ccus
61a
(µM)
61b
(µM)
61c
(µM)
61d
(µM)
61e
(µM)
61f
(µM)
61g
(µM)
61h
(µM)
61i
(µM)
62a
(µM)
62b
(µM)
62c
(µM)
62d
(µM)

>250

>250

>250

>250

250

250

>250

250

>250

>250

250

250

>250

250

>250

>250

250

250

>250

>250

>250

>250

250

250

>250

>250

>250

>250

200

250

>250

250

>250

>250

250

250

>250

250

>250

>250

250

250

>250

>250

>250

>250

>250

250

>250

250

>250

>250

250

>250

>250

>250

>250

>250

>250

250

>250

250

>250

>250

>250

250

>250

250

>250

>250

200

200

>250

>250

>250

>250

200

>250

DMSO was added to the control plate to be sure that it have no effect on the
bacterial growth of the selected bacteria and it shows no effect. Compounds 61e, 62c
and 62d show moderate inhibition activity against S.aureus at concentration 200 µM.
Compound 62c shows moderate inhibition activity against Enterococcus at
concentration 200 µM. Compounds 61a, 61b, 61c, 61f, 61g and 61i show inhibition
activity against P.aereginosa, S.aureus and Enterococcus at concentration 250 µM.
All compounds shows no inhibition activity against E.coli, Salmonella and
K.pneumoniae at consecration 250 µM.
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3.2.2 Antifungal activity
The antifungal activity of compounds (61a-i) and (62a-d) was tested against
mycelial growth of some selected plant diseases causal fungi: Fusarium solani (F3),
Botrytis cinerea (B), Thielaviopsis punctulata (T.P) and Neocystalidium dimediatum
(N.A). Plant diseases causal fungi are pathogenic and can be transferred to human by
eating the fruit or expose to the infected plant for example Fusarium solani found in
the soil and cause eye infections, Botrytis cinerea cause human hypersensitive
pneumoni, Thielaviopsis punctulata cause date palm diseases such as rhizosis and
black scorch (Al-Naemi et al., 2014) and Neocystalidium dimediatum cause skin
infection and foot infections (Machouart et al., 2013). Table 3 shows the
concentration of the compounds at which the fungi grow in.
Table 3: The concentration of the compounds (61a-i) and (62a-d) at which the
mycelial growth of some selected plant diseases causal fungi grow in
F.solani

B.cinerea

T.punctulata

N. dimediatum

61a(µM)

>100

>100

>100

>100

61b (µM)

>100

>100

>100

>100

61c (µM)

>100

>100

>100

>100

61d (µM)

>100

>100

>100

>100

61e (µM)

>100

>100

>100

>100

61f (µM)

>100

>100

>100

>100

61g (µM)

>100

>100

>100

>100

61h (µM)

>100

>100

>100

>100

61i (µM)

>100

>100

>100

>100

62a (µM)

>100

>100

>100

>100

62b (µM)

>100

>100

>100

>100

62c (µM)
62d (µM)

>100
>100

5µM
>100

>100
>100

>100
>100
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The DMSO was used as a control and it shows no effect on the fungi growth.
All compounds shows negative result at the concentration 100 µM against all types
of fungi which means ether the fungi need higher concentration than 100 µM to be
killed or the compounds not effective as an antifungal agent for these types of fungi.

3.3 Metal chelation results and discussion
Metal ions such as Cu+2, Zn+2 and Fe+3 play important role in many biological
processes in human body. The imbalance in the homeostatic amount of these metal
ions causes many diseases such as Alzheimer and Parkinson (Bernard, 2005). 8-HQ
is a potent chelating agent that may restore metal balance and is useful for the
treatment of diseases causeed by metal imbalance (Ibad et al., 2016).
The metal chelation properties of 10 compounds of 8-hydroxyquinoline-urea
(61a-i) and thiourea derivatives (62a-d) were studied in this research (Figure 36).
Since these compounds are not soluble in water, they were converted to the salt by
stirring them in 4M HCl in dioxane in order to make them soluble in water
(confirmed by NMR) and therefore their chelation properties with Cu

+2

, Zn+2 and

Fe+3 can be studied.

Figure 36: The metal chelation study was done for these 10 salt compounds
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The salt form of these compounds was treated with three metal ions Cu+2,
Zn+2 and Fe+3 as a copper sulfate , zinc acetate, Iron III chloride hexahydrate
solutions respectively in order to determine their chelation properties. Calibration
curve and interaction graphs with Cu+2, Zn+2 and Fe+3 of compound 62b.HCl are
shown as an example.The rest of compounds interaction graphs and calibration
curves are in the appendix.

3.3.1 Calibration curve for compound 62b.HCl
The calibration curve was constructed by studying the absorption at 240nm
with different concentration of compound 62b.HCl to determine the molar
absorptivity coefficient ( . Since = 1,

(Abs =

), which is the slope ( =

38209). The value of R2 close to 1, which means the values of

have good

correlation, see Figure 37.

1.2
0.9

1.0

0.8
Abs (240 nm)

Abs (a.u.)

0.8

0.7

y = 38209 x
2
R = 0.999

0.6

0.6
0.5

0.4

1.2

1.4

1.6

1.8

2.0

2.2

2.4

-5

[62.HCl] x 10 M

0.2
0.0

200

250

300
350
Wavelength (nm)

400

Figure 37: Calibration curve for compound 62b.HCl
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1. UV titration of 62b.HCl with Cu+2
Complex formation between 62.HCl with 2.39x10-5M concentration and Cu+2
ion was performed by gradual addition from 0 μL Cu+2 to 40 μL Cu+2 using 1.78x103

M solution stock of copper sulfate until saturation was reached at 40 μL. The graph

indicate a good interaction between the 62.HCl and the Cu+2 ion with three clear
isosbestic points at 249nm, 272nm & 238nm (Figure 38). Isosbestic points is a
specific wavelength at which the total absorbance does not change during the
addition of the metal to the sample.

1.2

2+

[Cu ]
0 ul
2 ul
4 ul
6 ul
10 ul
12 ul
14 ul
16 ul
18 ul
20 ul
25 ul
30 ul
35 ul
40 ul
50 ul

1.0

Abs (a.u.)

0.8
0.6
0.4
0.2
0.0
200

250

300

350

Wavelength (nm)

400

450

Figure 38: UV titration of 62b.HCl with Cu2+

2. UV titration of 62b.HCl with Zn+2
Complex formation between 62.HCl with 2.39x10-5M concentration and Zn+2
ion was performed by gradual addition From 0 μL Zn+2 to 260 μL Zn+2 using
1.78x10-3M solution stock of zinc acetate until saturation was reached at 260 μL
Zn+2. The graph indicate a good interaction between the 62.HCl and the Zn +2 ion
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with three clear isosbestic points at 248nm, 270nm & 238nm (Figure 39).

1.2

2+

[zn ]
0 ul Zn
2 ul Zn
4 ul Zn
10 ul Zn
20 ul Zn
40 ul Zn
60 ul Zn
80 ul Zn
100 ul Zn
120 ul Zn
140 ul Zn
170 ul Zn
200 ul Zn
230 ul Zn
260 ul Zn

1.0

Abs (a.u.)

0.8
0.6
0.4
0.2
0.0
200

250

300
350
Wavelength (nm)

400

450

Figure 39: UV titration of 62b.HCl with Zn2+

3. UV titration of 62b.HCl compound with Fe+3
Complex formation between 62.HCl with 2.39x10-5M concentration and Fe+3
ion was performed by gradual addition From 0 μL Fe+3 to 120 μL Fe+3 using
1.78x10-3 M solution stock of iron III chloride hexahydrate until saturation was
reached at 120 μL Fe+3. The graph indicate weak interaction between the 62.HCl and
the Fe+3 ion with no clear isosbestic point (Figure 40).
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3+

[Fe ]

1.2

0 ul Fe
2 ul Fe
4 ul Fe
6 ul Fe
8 ul Fe
10 ul Fe
12 ul Fe
14 ul Fe
16 ul Fe
18 ul Fe
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25 ul Fe
30 ul Fe
40 ul Fe
50 ul Fe
60 ul Fe
80 ul Fe
100 ul Fe
120 ul Fe

1.0

Abs (a.u.)

0.8
0.6
0.4
0.2
0.0
200

250

300

350

400

450

Wavelength (nm)

Figure 40: UV titration of 62b.HCl with Fe3+

All compounds show good interaction between the ligands and the metals as
indicated by the difference in the absorbance graph between free ligand and ligand
coordinated with the metal complex. There is also a systematic shift to the longer
wavelength (Bathochromic, Red shift), the absorbance decrease with the addition of
the metal (Hypochromic effect), and the isosbestic points appearance.
8-HQ derivatives were reported as bivalent metal ions chelator and the
complex stability follows Irving-Williams series (Mn2+ < Fe2+ < Co2+ < Ni2+ < Cu2+
> Zn2+), where the Cu ions form the most stable complexes (Shah et al., 2016). Same
trends were observed in our study, where the most stable complexes was with the
Cu2+ ions then with Zn2+ and Fe3+ complex was the less stable among them. The
strengths of the chelation was determined by the saturation amount needed, since the
consecration of the stock solution of the three metal ions was the same. The chelation
with Cu2+ needs from 25 µL to 60 µL of the metal ion solution to show the three
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clear isosbestic points. Binding to the Zn2+ ions needs higher amount (170-350 µL)
than the Cu2+ to show the isosbestic points. Fe3+ complex was the least stable and it
shows a very week interaction with no clear red shift and isosbestic points.

3.4 Photophysical results and discussion
In this part we studied the photophysical properties of 8-hydroxyquinolinecarbothioamide (61a-i), 8-hydroxyquinoline-carboxamide derivatives (62a-d) and 5chloromethyl-8-quinolinol as a control in the solid state (Figure 41).

Figure 41: The 8 compounds that their photophysical properties were studied

The intramolecular PET occurs from the 8-hydroxyquinoline ring (donor) to
the urea and thiourea group (acceptor) with the peprazine as a spacer between them.
A certain number of control molecules were exposed to a short pulse of light forming
an excited state (S1). The compounds return to the ground state (S0) either radiatively
(kr), non-raditively (knr), or by a rapid intramolecular PET quenching. The emission
maximum of the control was at 480 nm which belongs to the 8-HQ chromosphere.
The appearance of new peaks were observed in the presence of the acceptors (urea at
510 nm and thiourea at 620nm). The presence of multiple fluorophores renders the
PL spectra not reliable when it comes to determine the trend in the efficiency of
electron transfer as a function of the substituents in the solid state (Figure 42).
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Figure 42: The fluorescence peak for compounds 62b, 61c and control

However, from Table 4 in the absence of acceptor (control compound) the
excited-state lifetime (
process decrease

was at 6.9 ns. Monitored at the same wavelength, the PET

down to the range (0.2-2.9 ns) in the presence of different

acceptor . The shorter (

reflects higher PET efficiency.

Table 4: The fluorescence peak positions (nm) and excited-state lifetimes (ns) for
thiourea 8-HQ derivatives in solid state at room temperature
Compound
number
(substituent)

Emission peak
positions / nm

Excited-state
lifetimes for 8HQ at 480 nm /
ns*

Efficiency,
E (%) **

KPET ***

Control

483

6.9

61a (H)

505

1.4

80

0.57

61i (CF3)

636

1.5

78

0.52

61b (CH3)

507

1.6

77

0.48

61d (Cl)

508

1.9

72

0.38

61c (OCH3)

518

2.2

68

0.31
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Table 5: The fluorescence peak positions (nm) and excited-state lifetimes (ns) for
urea 8-HQ derivatives in solid state at room temperature
Compound
number
(substituent)

Emission peak
positions / nm

Excited-state
lifetimes for 8HQ at 480 nm /
ns*

Efficiency,
E (%) **

KPET ***

62a CH3

420

0.7

90

1.28

62c Cl

516

2.6

62

0.24

62b OCH3

508

3.0

57

0.19

*(

: Lifetime with radiative (kr), non-radiative (Knr) and PET processes

Before PET,

, After PET,

**Efficiency i = 1- , i= given compound.

It is plausible to rationalize the difference in PET efficiency by the molecular
stacking. For thiourea compounds, the efficiency of compounds 61a, 61i, 61b, 61d
and 61c were 80%, 78%, 77% , 72% and 68%, respectively depending on the size of
the substituent (Table 4). Compound 61a substituted with a small H atom and stack
together more effectively. The moderate size of Cl group in compounds 61d and 62c
lead to moderate efficiency (62%). The OCH3 group in compounds 61c and 62b
show lowest efficiency because of OCH3 bending nature. For urea compounds,
compound 62a with CH3 substituent has the highest efficiency (90%) compared to
these derivatives with Cl and OCH3 groups (62% versus 57%) by analogy to the
trend in data in the case of thiourea compounds (Table 5). However, the effects of
replacing the sulfur with oxygen on the efficiency becomes more significant when R
is a less bulky group.
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Chapter 4: Conclusion
This study includes the design and synthesis of a series of novel compounds
(61a-i) and (62a-d) containing 8-HQ, urea, thiourea and piperazine moieties to study
there biological activities and applications. These compounds were synthesized as
outlined in Figure 28 and the structures were established and confirmed by different
spectroscopic tools ( NMR, and IR).
All compounds (61a-i) and (62a-d) showed a negative result when studied
against selected 6 bacteria (Escherichia coli, Pseudomonas aeruginosa, Salmonella,
Klebsiella pneumonia, Staphylococcus aureus and

Enterococcus) and 4 fungi

(Fusarium solani, Botrytis cinerea, Thielaviopsis punctulata and Neocystalidium
dimediatum) at concentration of 100

.

The metal chelation studies for compounds (61a-i) and (62a-d) follows the
Irving-Williams series (Zn2+ < Cu2+ > Fe3+), where the Cu+2 ions form the most
stable complexes then the Zn+2 ions and the Fe+3 was forming the least stable
complex among them. All compounds shows three clear isobestic points around
250nm, 270nm and 340nm when interact with Cu2+ and Zn2+. Binding to Fe+3 ion
shows undefined isobestic points.
The results of the photophysical study indicated that there is a charge transfer
(PET) that occurs from the 8-HQ ring (donor) to the urea and thiourea group
(acceptor). The PET indicated by the appearance of new peaks in the presence of the
acceptors (urea at 510 nm and thiourea at 620nm ). The molecular stacking was
assumed as the factor for efficiency differences where the less bulky groups haveing
the highest efficiency (61a-62a). The efficiency of urea compounds was higher than
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thiourea presumably because the oxygen have smaller size than the sulfur.
Future studies on these compounds may include screening their in vitro
bioactivity against various human cancer cell lines. Additionally, more compounds
can by synthesized include changing the substituent from aryl urea and thiourea to
alkyl or benzyl. Moreover, the organic linker can be changed to ethylenediamine in
order to have a better understanding of these systems.
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Appendix
(1H-NMR& 13CNMR data)
Synthesis of 5-chloromethyl-8-quinolinol hydrochloride (55)

Figure 43: 1H-NMR (400 MHz, D2O) spectra of 55

Figure 44: 13C-NMR (100 MHz, D2O) spectra of 55

67
Ttert-butyl 4-((8-hydroxyquinolin-5-yl)methyl)piperazine-1-carboxylate (57)

Figure 45: 1H-NMR (400 MHz, CDCl3) spectra of 57

Figure 46: 13C-NMR (100 MHz, CDCl3) spectra of 57
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Synthesis of 5-piperazineomethyl-8-hydroxyquinoline (58)

58

58

Figure 47: 1H-NMR (400 MHz, DMSO-d6) spectra of 58

Figure 48: 13C-NMR (100 MHz, DMSO-d6) spectra of 58
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4-((8-hydroxyquinolin-5-yl)methyl)-N-phenylpiperazine-1-carbothioamide (61a)

Figure 49: 1H-NMR (400 MHz, DMSO-d6) spectra of 61a

Figure 50: 13C-NMR (100 MHz, DMSO-d6) spectra of 61a
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4-((8-hydroxyquinolin-5-yl)methyl)-N-(p-tolyl)piperazine-1-carbothioamide (61b)

Figure 51: 1H-NMR (400 MHz, CDCl3) spectra of 61b

Figure 52: 13C-NMR (100 MHz, CDCl3) spectra of 61b
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4-((8-hydroxyquinolin-5-yl)methyl)-N-(4-methoxyphenyl)piperazine-1carbothioamide (61c)

Figure 53: 1H-NMR (400 MHz, DMSO-d6) spectra of 61c

Figure 54: 13C-NMR (100 MHz, DMSO-d6) spectra of 61c
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N-(4-chlorophenyl)-4-((8-hydroxyquinolin-5-yl)methyl)piperazine-1-carbothioamide
(61d)

Figure 55: 1H-NMR (400 MHz, DMSO-d6) spectra of 61d

Figure 56: 13C-NMR (100 MHz, DMSO-d6) spectra of 61d
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4-((8-hydroxyquinolin-5-yl)methyl)-N-(4-nitrophenyl)piperazine-1-carbothioamide
(61e)

Figure 57: 1H-NMR (400 MHz, DMSO-d6) spectra of 61e

Figure 58: 13C-NMR (100 MHz, DMSO-d6) spectra of 61e
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N-(2-fluorophenyl)-4-((8-hydroxyquinolin-5-yl)methyl)piperazine-1-carbothioamide
(61f)

Figure 59: 1H-NMR (400 MHz, DMSO-d6) spectra of 61f

Figure 60: 13C-NMR (100 MHz, DMSO-d6) spectra of 61f
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N-(3-fluorophenyl)-4-((8-hydroxyquinolin-5-yl)methyl)piperazine-1-carbothioamide
(61g)

Figure 61: 1H-NMR (400 MHz, DMSO-d6) spectra of 61g

Figure 62: 13C-NMR (100 MHz, DMSO-d6) spectra of 61g
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N-(4-fluorophenyl)-4-((8-hydroxyquinolin-5-yl)methyl)piperazine-1-carbothioamide
(61h)

Figure 63: 1H-NMR (400 MHz, DMSO-d6) spectra of 61h

Figure 64: 13C-NMR (100 MHz, DMSO-d6) spectra of 61h
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4-((8-hydroxyquinolin-5-yl)methyl)-N-(4-(trifluoromethyl)phenyl)piperazine-1carbothioamide (61i)

Figure 65: 1H-NMR (400 MHz, DMSO-d6) spectra of 61i

Figure 66: 13C-NMR (100 MHz, DMSO-d6) spectra of 61i
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4-((8-hydroxyquinolin-5-yl)methyl)-N-(p-tolyl)piperazine-1-carboxamide (62a)

Figure 67: 1H-NMR (400 MHz, DMSO-d6) spectra of 62a

Figure 68: 13C-NMR (100 MHz, CDCl3) spectra of 62a
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4-((8-hydroxyquinolin-5-yl)methyl)-N-(4-methoxyphenyl)piperazine-1-carboxamide
(62b)

Figure 69: 1H-NMR (400 MHz, DMSO-d6) spectra of 62b

Figure 70: 13C-NMR (100 MHz, DMSO-d6) spectra of 62b
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N-(4-chlorophenyl)-4-((8-hydroxyquinolin-5-yl)methyl)piperazine-1-carboxamide
(62c)

Figure 71: 1H-NMR (400 MHz, DMSO-d6) spectra of 62c

Figure 72: 13C-NMR (100 MHz, DMSO-d6) spectra of 62c
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4-((8-hydroxyquinolin-5-yl)methyl)-N-(4-nitrophenyl)piperazine-1-carboxamide
(62d)

Figure 73: 1H-NMR (400 MHz, DMSO-d6) spectra of 62d

Figure 74: 13C-NMR (100 MHz, DMSO-d6) spectra of 62d
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IR spectra for compounds (61a-i) and (62a-d)

Figure 75: Infrared spectra for (61a), (61b) and (61c)

83

Figure 76: Infrared spectra for (61d), (61e) and (61f)
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Figure 77: Infrared spectra for (61g), (61h) and (61i)
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Figure 78: Infrared spectra for (62a), (62b) and (62c)
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Figure 79: Infrared spectra for (62d)

87
Metal Chelation graphs

Figure 80: 61a.HCl Calibration table and curve

Figure 81: UV titration of 61a.HCl with Cu2+
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Figure 82:UV titration of 61a.HCl with Zn2+

Figure 83: 61b.HCl Calibration curve
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Figure 84:UV titration of 61b.HCl with Cu2+

Figure 85:UV titration of 61b.HCl with Zn2+
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Figure 86: 61c.HCl Calibration curve

Figure 87:UV titration of 61c.HCl with Cu2+
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Figure 88: UV titration of 61c.HCl with Zn2+

Figure 89:UV titration of 61c.HCl with Fe3+
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Figure 90: 61d.HCl calibration curve

Figure 91:UV titration of 61d.HCl with Cu2+
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Figure 92: UV titration of 61d.HCl with Zn2+

Figure 93: 61h.HCl calibration curve
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Figure 94: UV titration of 61h.HCl with Cu2+

Figure 95:UV titration of 61h.HCl with Zn2+
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Figure 96: 61i.HCl calibration curve

Figure 97: UV titration of 61i.HCl with Cu2+
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Figure 98: UV titration of 61i.HCl with Zn2+

Figure 99: 62a.HCl calibration curve
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Figure 100: UV titration of 62a.HCl with Cu2+

Figure 101: UV titration of 62a.HCl with Zn2+
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Figure 102: 62b.HCl Calibration curve

Figure 103: UV titration of 62b.HCl with Cu2+
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Figure 104: UV titration of 62b.HCl with Zn 2+

Figure 105: UV titration of 62b.HCl with Fe3+
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Figure 106: 62c.HCl Calibration curve

Figure 107: UV titration of 62c.HCl with Cu2+
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Figure 108: UV titration of 62c.HCl with Zn2+

Figure 109: UV titration of 62c.HCl with Fe3+
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Figure 110: 62d.HCl Calibration curve

Figure 111: UV titration of 62d.HCl with Cu+2
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Figure 112: UV titration of 62d.HCl with Zn2+
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Figure 113: Steady-state emission spectra for control, compounds (61a-b) and (62ab) in solid state at room temperature (
)
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Figure 114: Steady-state emission spectra for compounds (61c-d) and (61h-i)in solid
state at room temperature (
)

Digitally signed by
Shrieen
DN: cn=Shrieen,
o=United Arab
Emirates University,
ou=UAEU Library
Digitizatio,
email=shrieen@uae
u.ac.ae, c=AE
Date: 2021.07.13
13:22:02 +04'00'

